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TERMS AND ABBREVIATIONS 
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ä  Trademark 
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AE Adverse Event 
ALT Alanine aminotransferase 
ASC Antibody Secreting Cells 
AST Aspartate aminotransferase 
BP Blood Pressure 
CFR Code of Federal Regulations 
CFU Colony Forming Units 
CRF Case Report Form 
CV Curriculum Vitae 
ELISA Enzyme Linked ImmunoSorbant Assay 
ELISPOT Enzyme Linked ImmunoSpot Assay 
g Gram 
GCP Good Clinical Practice 
gGT Gamma-glutamyl transferase 
HIV Human Immunodeficiency Virus 
IB Investigator’s Brochure  
ICH International Conference on Harmonisation 
IFNg Gamma-interferon 
IgA Immunoglobulin A 
IgG Immunoglobulin G 
IMP Investigational Medicinal Product 
IRB Institutional Review Board 
ITT Intent-to-treat 
LPS Lipopolysaccharide 
MALT Mucosal Associated Lymphoid Tissue 
MedDRA Medical Dictionary for Regulatory Activities 
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mg Milligram 
MIC Minimum Inhibitory Concentration 
mL Millilitre 
PBMC Peripheral Blood Mononuclear Cells 
PP Per protocol 
RES Reticulo-endothelial system 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SD Standard Deviation 
SDV Source Data Verification 
SPI-2  Salmonella Pathogenicity Island 2 
UK United Kingdom 
w/v Weight per Volume 
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Amendments 
Protocol Amendment 1 
Date of Preparation of Amendment: 17 January 2007 
Reason for Amendment 
 
The reasons for this amendment are given below: 
a. The sponsor has delegated the management of SAE reporting to the specialised SAE 
Management and safety surveillance organisation, AKOS Ltd. 
b. The statistician for the trial has now changed due to personnel changes at Statwood the 
statistical group contracted to conduct the data management and statistical analysis. 
c. Plans to conduct a long term follow-up (MS01.10) in these subjects have been 
discontinued. 
d. Minor administrative and typographic amendments have also been made to aid 
understanding and for internal consistency.  
 
These changes do not affect the procedures that the subjects will undergo with respect to this 
protocol and have no impact of the written information provided to the subject.  
 
Specific Changes  
 
Location Original Text  New Text  
Page 3 None- New text added. CONTACT FOR SERIOUS 
ADVERSE EVENT REPORTING 
AKOS Ltd. 
The Coach House 
The Grove 
Pipers Land,  
Harpenden 
Herts, AL5 1AH 
 
Telephone: 01582 766339 
Fax:   01582 764327 
Fax Number for SAE Reporting:
 xxxxxxxxxxxxx 
E-Mail xxxxxxxxxxxxxxxxxxxxx 
Page 7 “xxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxx”  “ 
..“xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxx”… 
2.7   Risks and 
Benefits 
…“The anticipated risks of the study are in 
line with the side effect profile seen to date 
with M01ZH09.  The most likely adverse 
effects are flatulence, abdominal 
…“The anticipated risks of the study are 
in line with the side effect profile seen 
to date with M01ZH09.  The most likely 
adverse effects are flatulence, 
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cramps/discomfort, loose/unformed stools, 
headache, nausea, vomiting, chills/rigors, 
minor elevations in body temperature (to 
< 38oC) and mild muscle and joint pain in 
subjects receiving the active vaccine.”… 
 
abdominal cramps/discomfort, 
loose/unformed stools, headache, 
nausea, vomiting, chills/rigors, minor 
elevations in body temperature (up to 
38°C) and mild muscle and joint pain in 
subjects receiving the active vaccine.”… 
Section 4.5   
Blinding 
“The investigational products will be 
blinded by dispensing the dosing solutions 
in unmarked beakers and will be controlled 
and dispensed by the clinic pharmacist 
according to the pre-prepared 
randomisation lists.  Hence the investigator 
will be essentially blinded in that 
knowledge of the product supplied to the 
subjects will remain unknown.  “… 
“Active vaccine and matching placebo 
will be packaged identically but with a 
unique sequential number. This number 
will enable identification of the contents 
in case of emergency when used with 
the randomisation code break. 
Preparation of both active and placebo 
doses will be identical. Hence the 
investigator and his staff will be 
essentially blinded in that knowledge of 
the product supplied to the subjects will 
remain unknown.”   
Section 4.7   
Duration of 
Subject 
Participation 
   “six months.  All subjects will be invited 
to take part in a long-term follow-up study 
MS01.10.”   
   “six months.   
6.8.2   Visit 1: 
Day of Dosing/ 
Day 0 
 
· Enquire about and record any changes 
in concomitant medication since screening. 
 
· Enquire about and record any 
changes in concomitant medication 
since screening 
If the subject has received antibiotic 
therapy within 14 days of this visit, 
arrange for the subject to return for 
dosing if this is possible within 28 
days of the screening visit. If not, 
please withdraw the subject from the 
study. 
Subjects who are withdrawn at Visit 
1, under these circumstances and 
cannot be dosed within 28 days of the 
Screening Visit may be re-screened. 
Under these circumstances the 
subject must be re-consented.  
6.8.2   Visit 1: 
Day of Dosing/ 
Day 0 
 
· Determine and record vital signs (blood 
pressure, temperature and pulse).  
 
· Determine and record vital signs 
(blood pressure, temperature and pulse).  
If oral temperature is 38°C or more, 
arrange for the subject to return for 
dosing if this is possible within 28 
days of the screening visit. If not, 
please withdraw the subject from the 
study. 
Subjects who are withdrawn at Visit 
1, under these circumstances and 
cannot be dosed within 28 days of the 
Screening Visit may be re-screened. 
Under these circumstances the 
subject must be re-consented. 
6.8.2   Visit 1: 
Day of Dosing/ 
· Make an appointment for Study Day 1 · Make an appointment for Visit 2/ 
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Day 0 
 
and  instruct the subject to bring a stool 
sample to the visit. 
 
Day 1 and instruct the subject to bring a 
stool sample to the visit. 
 
8.1.2   Serious 
Adverse Event 
 
…“reported to Emergent Product 
Development UK Ltd following the SAE 
reporting procedure.   If the blood culture 
grows the M01ZH09 vaccine strain or if the 
cause of the bacteraemia is undetermined 
Emergent Product Development UK Ltd 
will report the event as a serious, 
unexpected, related, adverse event.”.. 
…“reported to Akos Ltd. following the 
SAE reporting procedure.   If the blood 
culture grows the M01ZH09 vaccine 
strain or if the cause of the bacteraemia 
is undetermined Akos Ltd. will report 
the event as a serious, unexpected, 
related, adverse event.”.. 
8.2   Collection, 
Recording and 
Reporting of 
Adverse Events 
 
“All SAEs, whether or not they are judged 
to be related to the study drug, should be 
reported, by the Investigator, to Emergent 
Product Development UK Ltd, upon 
learning of the SAE.  SAEs must be 
reported within 24 hours of knowing about 
the event or, ideally, within 24 hours of the 
occurrence of the event.  The Investigator 
must complete the Emergent Product 
Development UK Ltd SAE form with as 
much information as is available at the time 
of completion and fax the form immediately 
to the number provided. The Study 
Monitor, the Medical Monitor, or a 
representative of Emergent Product 
Development UK Ltd, may follow up by 
requesting clarification or additional 
information on the SAE, from the 
Investigator.”… 
 
…“It is the responsibility of the Investigator 
(with the assistance of Emergent Product 
Development UK Ltd ) to report any 
serious, unexpected ADRs to the Ethics 
Committee in accordance with ICH 
guidelines and local requirements.”… 
 
“All SAEs, whether or not they are 
judged to be related to the study drug, 
should be reported, by the Investigator, 
to Akos Ltd. , upon learning of the SAE.  
SAEs must be reported within 24 hours 
of knowing about the event or, ideally, 
within 24 hours of the occurrence of the 
event.  The Investigator must complete 
the Akos Ltd. SAE form with as much 
information as is available at the time of 
completion and fax the form 
immediately to the number provided. 
Akos Ltd.,  the Study Monitor, the 
Medical Monitor, or a representative of 
Emergent Product Development UK 
Ltd, may follow up by requesting 
clarification or additional information 
on the SAE, from the Investigator.”… 
 
It is the responsibility of the Investigator 
(with the assistance of Emergent 
Product Development UK Ltd and/or 
Akos Ltd.  to report any serious, 
unexpected ADRs to the Ethics 
Committee in accordance with ICH 
guidelines and local requirements.”… 
 
8.3  Follow-up of 
Adverse Events 
…“The Investigator must forward follow-
up information on SAEs to Emergent 
Product Development UK Ltd within 5 days 
of obtaining the follow-up information.  
Only changed or new information should be 
supplied.”… 
…“The Investigator must forward 
follow-up information on SAEs to Akos 
Ltd. within 5 days of obtaining the 
follow-up information.  Only changed 
or new information should be 
supplied.”… 
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1 PROTOCOL SUMMARY 
Protocol Number MS01.08 V2 
Title of the Study A placebo-controlled, single-blind, single oral dose study to 
determine the safety and immunogenicity of  M01ZH09 typhoid 
vaccine (oral live S. typhi (Ty2 aroC? ssaV?) ZH9) in healthy 
paediatric subjects, aged 5 to 14 years inclusive, of Vietnamese 
origin. 
Sponsor Emergent Product Development UK Ltd (formerly Microscience 
Ltd) 
Phase of Development Phase II 
Regulatory Status  IND No. BB-IND 10176 
STUDY OBJECTIVES 
Primary To evaluate the safety and immunogenicity of M01ZH09 typhoid 
vaccine (oral live S. typhi (Ty2 aroC? ssaV?) ZH9) at a nominal 
dose of 5 x 109 colony forming units (CFU) in healthy paediatric 
subjects from Viet Nam. 
Study Design A single centre, single-blind, placebo-controlled, randomised, 
parallel group study. 
SUBJECT POPULATION 
Number of Subjects 150 subjects will be randomised and receive M01ZH09 oral 
typhoid vaccine or placebo in a 2:1 ratio (100 active : 50 placebo) 
Number of Groups  2 groups of subjects. 
1.  100 subjects will receive M01ZH09 
2.  50 subjects will receive placebo. 
At least 70% of the subjects in each group will be aged 5 to 10 
years inclusive. 
Status/ Sex/ Age Healthy male and female paediatric subjects aged 5 to 14 
inclusive. 
Study Groups  Group 1.  Subjects will receive a nominal dose of 5 x 109 CFU of 
M01ZH09 typhoid vaccine.  Vaccine will be administered in a 
bicarbonate solution containing 1.75% (w/v) sodium bicarbonate, 
1.1% (w/v) ascorbic acid and 0.02% (w/v) aspartame.  The 
solution is prepared from bicarbonate tablets using drinking water. 
Group 2.  Subjects will receive placebo administered in a 
bicarbonate solution containing 1.75% (w/v) sodium bicarbonate, 
1.1% (w/v) ascorbic acid and 0.02% (w/v) aspartame.  The 
solution is prepared from bicarbonate tablets using drinking water. 
Subjects aged 5 to 10 years will receive the vaccine or placebo in 
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75 mL of bicarbonate solution.  Subjects aged 11 to 14 years will 
receive the vaccine or placebo in 150 mL of bicarbonate solution. 
Study Medication S. typhi (Ty2 aroC? ssaV?) ZH9 at a nominal dose of 5 x 109 CFU. 
M01ZH09 is supplied as a freeze-dried formulation of the vaccine 
strain, plus excipients, in single dose vials.  The placebo is 
supplied as a freeze-dried formulation of vaccine excipients only, 
in single dose vials.  Effervescent bicarbonate tablets containing, 
sodium bicarbonate, ascorbic acid and aspartame will also be 
supplied. 
Dosing Regimen Single oral dose. 
Inclusion Criteria 1. Healthy paediatric subjects aged 5 to 14 years inclusive, of 
Vietnamese origin, who are able and willing to take part in the 
trial and whose parents or guardians give written permission 
for their child’s participation, following a detailed explanation 
of the study. 
2. Subjects who will be available for the duration of the study 
and available for scheduled and potential additional visits. 
Exclusion Criteria 1. Subjects with any clinically significant medical or psychiatric 
condition or clinically significant abnormal serum 
biochemistry or haematology results that, in the opinion of the 
Investigator, preclude participation in the study. 
2. Subjects whose body weight is under 17kg (5-10 year olds), or 
under 27kg (11-14 year olds) 
3. Female subjects who are pregnant (confirmed with urinary 
pregnancy test) or breast-feeding, or of childbearing potential 
and unwilling to use a reliable method of contraception (oral 
contraceptives, barrier method with spermicidal preparation or 
abstinence) throughout the study period. 
4. Subjects who have a known hypersensitivity to two or more of 
the following antibiotics; ciprofloxacin, azithromycin or 
trimethoprim-sulfamethoxazole or have used 
antibiotics/antibacterials within 14 days prior to administration 
of study medication. 
5. Subjects who have a known hypersensitivity to any component 
of the vaccine or bicarbonate solution used in this study, 
including subjects with phenylketonuria or those who have 
ever experienced anaphylactic shock after any vaccination. 
6. Subjects who received Vivotif, either as a licensed or 
investigational product, in the last 10 years or any other 
vaccine against S. typhi, whether licensed or investigational, in 
the last 5 years, or who have ever suffered from typhoid fever. 
7. Subjects with direct contact with patients in special care units 
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or immuno-compromised individuals. 
8. Subjects who have a positive bacterial culture of their faecal 
sample, obtained at the screening visit, for any Salmonella 
species. 
9. Subjects with a known impairment of immune function 
including acquired immune deficiency syndrome or those 
receiving (or having received in the 6 months prior to 
screening) cytotoxic drugs, immunosuppressive therapy 
(including systemic corticosteroids). 
10. Subjects who are HIV positive or have family members who 
are HIV positive.  (‘Family members’ includes immediate and 
extended family living in the same residential unit, or relations 
with whom the subject has regular and frequent contact). 
11. Subjects with a significant acute febrile illness (body 
temperature of 38.0ºC or more) at time of dosing. 
12. Subjects who have chronic diseases: Chronic diseases will 
include all autoimmune and immuno-compromising conditions 
and any other chronic condition which, at the judgement of the 
Investigator, may put the subject at higher risk of side effects 
from the study vaccine.  Conditions in the latter category might 
include unexplained anaemia, hepato-biliary disease, 
uncontrolled hypertension, subjects with prosthetic joints or 
heart valves etc. 
13. Subjects with a current problem, based on history, of substance 
abuse or with a history of substance abuse that, in the opinion 
of the investigator, might interfere with participation in the 
study. 
14. Subjects who are currently involved in a clinical study, have 
taken an investigational drug or have received investigational 
or licensed vaccines in the 4 weeks before screening, or 
anticipate receiving a vaccine, other than study medication, 
during the first 4 weeks, post vaccination, of the study. 
Study Conduct/ 
Procedures 
Following completion of the screening assessment, subjects who 
satisfy the study entry criteria will be randomised to one of the two 
treatment groups (active or placebo) and will receive medication 
on Day 0.  Subjects will then return to the investigative site every 
day until Day 14, and then again on Day 28, for assessment of 
safety and immunogenicity and to provide blood, urine and stool 
samples as required (see schedule of events).  Subjects will record 
their oral temperatures on a Diary Card, twice daily, for the first 
14 days following dosing and will return to the clinic for 
additional visits should they develop fever or other signs 
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potentially indicating a bacteraemia. 
Safety Endpoints Primary 
The proportion of subjects reporting Serious Adverse Events 
attributed to the study medication. 
Secondary 
Proportion of subjects; 
· Experiencing an elevated body temperature of 38.5°C or 
greater, in the 14 days following dosing, attributed to study 
medication. 
· Demonstrating persistent (after Day 7) faecal shedding of S. 
typhi (Ty2 aroC?ssaV?) ZH9. 
· Withdrawn from the study due to adverse events, including 
bacteraemia attributed to study medication. 
· With clinically significant changes in laboratory parameters, 
from Day 0 to any time post dosing, which are attributed to 
study medication. 
Immunogenicity 
Endpoints 
Assessment of the immune response will be made by determining 
the proportion of subjects who; 
· Develop a positive immune response* to S. typhi 
lipopolysaccharide (LPS) as assessed by an increase in S. typhi 
LPS specific IgG at either Day 14 or Day 28. 
· Develop a positive immune response* to S. typhi LPS as 
assessed by an increase in S. typhi LPS specific IgA at either 
Day 7 or Day 14. 
· At Day 7, have = 4 antibody secreting cells (ASCs) per 106 
peripheral blood mononuclear cells (PBMC), secreting IgA 
specific for S. typhi LPS detected by ELISPOT assay. 
*The definition of a ‘positive immune response’ will be 
determined following the completion of assay development. 
Statistical Analyses The primary outcome measure in this study will be the proportion 
of subjects with a positive immune response (a positive serum IgG 
and/or a positive serum IgA response and/or an increase in the 
number of PBMC secreting IgA specific for S.typhi detected by 
ELISPOT assay).  The proportion of subjects who satisfy the 
immunogenicity endpoint will be compared between the vaccine 
and placebo groups.  The treatment difference and associated 95% 
confidence interval will be presented. 
The number and percentage of subjects with an immune response 
will be presented along with the two-sided 95% confidence 
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interval for each treatment group. 
In addition, the number and percentage of subjects with defined 
immune response will be presented by type of assay. 
For the safety endpoints, the proportion of subjects that have a 
SAE, attributed to the study medication, will be compared 
between groups.  The proportion of subjects with symptomatic 
elevation in body temperature, persistent faecal shedding and 
clinically significant changes in laboratory parameters will be 
compared between groups. 
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1.1 Study Schedule 
Visit Screen 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Day  -28 to -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 28 
Informed Permission and Assent X                 
Inclusion/exclusion criteria X X1                
Demography/medical history X X                
Medication history (particularly antibiotics) X X                
Physical examination X                X 
Vital signs2 X X X X X X X X X X X X X X X X X 
Blood draw for HIV X                 
Issue digital thermometer  X                
Issue Diary card  X                
Review data on Diary Card   X X X X X X X X X X X X X X  
Review adverse events   X X X X X X X X X X X X X X X X 
Review splenomegaly X X X X X X X X X X X X X X X X X 
Review changes in concomitant medications  X X X X X X X X X X X X X X X X 
Dosing  X                
Laboratory – safety:                  
Blood draw for haematology and biochemistry X X       X       X X 
Urine pregnancy test, if applicable3 X X               X 
Urinalysis (dip stick)4 X X       X       X X 
Stool culture5 X X X X X X X X X X X X X X X X  
Laboratory – immunogenicity:                  
Blood draw for IgG (serum ELISA) assay  X              X X 
Blood draw for IgA (serum ELISA) assay  X       X       X  
PBMC Blood draw for ELISPOT assay6  X       X         
 
1.   On receipt of screening visit laboratory results, check that the subject is still eligible for study entry. 
2.  Oral temperature, blood pressure and pulse rate conducted prior to dosing on Day 0 and then on each subsequent study visit.  Subjects will take their own temperature or have 
their temperature taken, daily, in the morning when they get up and when they go to bed for Days 1 through 14 and record the reading on their Diary Cards. (On day of dosing, 
blood pressure and pulse will be taken 30, 60 and 90 minutes post dose). 
3.  For all female subjects aged 11 years and older. 
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4.  If urine dipstick test shows presence of nitrites and leucocyte esterase, a fresh urine sample will be sent for microscopy, culture and sensitivity.  Additionally at V8, 15 and 16 
cultures to determine if S.typhi (Ty2 aroC? ssaV?) ZH09 is present will also be performed 
5.  Stool samples will be sent for culture of Salmonella spp and in addition at V2-15 to determine if vaccine strain S.typhi (Ty2 aroC? ssaV?) ZH09 is present. 
6.  ELISPOT assay to be performed only on subjects aged at least 11 years. 
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2 BACKGROUND INFORMATION 
2.1 Typhoid Disease 
Typhoid fever is an acute, generalised infection of the reticuloendothelial system (RES), intestinal 
lymphoid tissue and gall bladder caused by Salmonella enterica serovar Typhi (S. typhi).  It is 
restricted to causing human disease and therefore humans (chronic carriers) serve as the 
epidemiological reservoir of infection. 
The disease is spread orally through the ingestion of contaminated food and water.  S. typhi is 
highly invasive and, once ingested, passes through the intestinal mucosa to reach the lamina 
propria.  Shortly after this a primary bacteraemia takes place, during which the S. typhi are filtered 
from the circulation by fixed phagocytic cells of the RES.  As a result of this primary bacteraemia, 
the pathogen rapidly attains an intracellular haven throughout the organs of the RES where it 
resides during the incubation period (usually 8 to 14 days) until the onset of clinical typhoid fever.  
Clinical illness is accompanied by a sustained secondary bacteraemia. 
In populations in developing countries that are not served with treated water supplies and sanitation 
to remove human waste, typhoid fever is endemic. There are approximately 17 million cases of 
typhoid fever reported globally every year, but as not all cases are reported it has been estimated 
that the true figure may be as high as 30 million cases globally.  There are 600,000 deaths per 
annum worldwide attributed to typhoid fever, nearly all of these occurring in developing countries.  
Some three-quarters of the global burden occurs in Asia; the bulk of which is borne by pre-school 
and school-aged children. In South Viet Nam, typhoid fever remains a significant intestinal 
infection. Between 1990 and 1993, among 15 districts in the South of the country, a total of 3,853 
to 9,179 cases per year were registered.  Of these there were from 8 to 31 deaths. In 1993 an 
epidemic of typhoid fever broke out in the An Minh district (territory of Kien Giang, South Viet 
Nam), affecting 3,049 people and causing two deaths. Of the 574 blood samples analysed, 266 
strains of S. typhi were isolated (Nguyen, Ha Ba and Nguyen 1993).  Viet Nam, particularly in the 
southern provinces, experienced a greater than six-fold increase in reported cases of typhoid fever 
from 1990 (4,859 cases) to 1995 (30,901). Most cases (90%) were reported from the southern 
region which consists of 17 provinces that comprise about 39% of the total population of Viet Nam.  
Typhoid is a significant disease in pre-school and school children in Viet Nam. 
Typhoid fever has become difficult and expensive to treat.  In southern Viet Nam, about 90% of S. 
typhi isolates are now resistant to multiple antibiotics including chloramphenicol, ampicillin and co-
trimoxazole.  More recently, 76% of blood culture isolates of S. typhi were reported to be resistant 
to nalidixic acid (Lin et al 2000).  Over the last few years, the incidence of typhoid fever in Viet 
Nam has decreased but still occurs. 
The increasing prevalence of S. typhi strains exhibiting resistance to multiple, previously effective, 
antibiotics has complicated the therapy of typhoid fever, and has rekindled the interest in the 
development of more effective typhoid vaccines. 
Inactivated (heat-killed, phenol-preserved) vaccines have been used for many years and have been 
shown to confer moderate protection (Levine, 1994).  However, they were never well accepted as 
public health tools because of the adverse systemic reactions that occurred with high frequency 
(about 25%) in the recipients of such vaccines.  Two newer vaccines have now superseded the 
whole cell vaccines, a purified Virulence antigen (Vi) polysaccharide vaccine and an orally 
delivered live attenuated vaccine. 
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In the 1970s and early 1980s methods were developed to purify the Vi polysaccharide antigen from 
S. typhi.  The purified Vi vaccine is free from contaminating Lipopolysaccharide (LPS), which is 
associated with systemic adverse events in injectable whole cell vaccines.  Vi is an essential 
virulence factor and antibodies against the antigen are protective against typhoid disease.   In field 
studies purified Vi has proved to be well tolerated (around 1 to 2% of recipients have febrile 
reactions) and confers efficacy of around 70% after a single dose (Klugman et al., 1987, Klugman 
et al., 1996; Achayra et al., 1987).  Purified Vi vaccines (Typhim-Vi, Aventis Pasteur MSD and 
Typherix, SmithKline Beecham) are commercially available, have similar efficacy to that of the 
whole cell vaccines (Achayra et al., 1987) and have replaced the killed whole cell vaccines as the 
parenteral vaccine of choice.  Like other polysaccharide vaccines, immune responses to Vi are age-
related and it is not very immunogenic in children.  It is also a T cell- independent antigen and it is 
not possible to boost the primary response.  There is clearly room for improvement in terms of 
immunogenicity, induction of immunological memory and protective efficacy of these vaccines. 
Conjugated vaccines are now under development that can potentially overcome these issues.  Trials 
of a conjugate of Vi to a non-toxic recombinant Pseudomonas aeruginosa exotoxin A are 
promising, demonstrating that this vaccine is safe and immunogenic, has more than 90% efficacy in 
children 2 to 5 years old, gives enhanced immunogenicity in adults and children of 5 to 14 years old 
(Kossaczka et al., 1999) and was able to elicit a booster response in children of 2 to 4 years (Lin et 
al., 2001). 
S. typhi Ty21a (Vivotif Berna™ , Berna) is a live attenuated S. typhi strain.  It was attenuated using 
rounds of chemical mutagenesis and is Vi negative (Germanier and Furer, 1975).  The exact 
mechanism of attenuation is unknown.  This vaccine has demonstrated variable efficacy in several 
controlled field studies using different formulations.  However, in order for the vaccine to be 
effective it has to be given in multiple doses (three in Europe and four in the US) and recipients 
have to remember to take the additional doses, and this raises a compliance issue.  Once again, there 
is clearly room for improvement, both in terms of efficacy and convenience. 
It is well established that live attenuated organisms can be highly effective vaccines, immune 
responses elicited can often be of greater magnitude and of longer duration than those produced by 
non- living antigens (Collins 1974; Hormaeche et al., 1990), and are often able to confer protection 
after a single dose.  This is probably because these attenuated strains are able to mimic the early 
stages of natural infection.  In addition, unlike killed preparations, live Salmonella vaccines are able 
to induce potent cell mediated responses (Sztein et al., 1994, 1995; Gonzalez et al., 1994), which 
may be connected with their ability to replicate in antigen-presenting cells such as macrophages.  T 
cell proliferation, cytokine production, cytotoxic T cell responses and antibody-dependent cell 
cytotoxicity have all been elicited by live attenuated S. typhi vaccines (Levine and Sztein, 1996). 
For the majority of pathogens, the first contact with the host is at a mucosal surface and the specific 
and non-specific immune mechanisms operating at these surfaces play a major role as the first line 
of defence.  Thus, when considering new vaccine strategies to combat organisms that invade 
mucosal surfaces, it is important to consider priming the mucosal-associated lymphoid tissue 
(MALT) in order to maximize the effectiveness of vaccination.  Unfortunately, parenteral 
vaccination is not efficient at eliciting mucosal responses as the primary requirement for such 
responses is contact of the immunogen directly with the mucosal surface (McGhee et al., 1992). 
One of the most desirable ways to deliver a vaccine is via the oral route, which avoids the use of 
needles and reduces systemic reactogenicity. However, non–living vaccines, including S. typhi 
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vaccines (DuPont et al., 1971; Chuttani et al., 1973), are poor at eliciting either a mucosal or 
systemic response when given orally. 
The advantage of a live Salmonella vaccine therefore, is that it can be given orally (which is the 
natural route of infection), and live salmonellae are known to stimulate potent humoral, cellular and 
secretory anti-Salmonella responses (Chatfield et al., 1993).  
There has been a history of the use of live attenuated Salmonella vaccines as safe and effective 
vaccines for the prevention of salmonellosis in animals and humans.  Ty21a (Vivotif Berna™) has 
proved to be a very successful vaccine for the prevention of typhoid fever.  However, as ment ioned 
above, the attenuation of this strain was achieved using chemical mutagenesis techniques and the 
basis of attenuation of the strain is not fully understood.  In addition it is difficult to use chemical 
mutagenesis to prepare a vaccine with optimal immunogenicity. 
The advent of modern molecular biology techniques, coupled with the increasing knowledge of 
Salmonella pathogenesis has led to the identification of several genes that are essential for the in 
vivo growth and survival of the organisms.  This has provided new gene targets for attenuation, 
leading to the concept that introducing defined non-reverting mutations into selected genes known 
to be involved in virulence can ‘rationally’ attenuate future vaccine strains.  This has facilitated the 
development of improved vaccines, particularly in terms of increasing the immunogenicity and 
therefore reducing the number of doses that have to be given. 
This study is designed to investigate the immunogenicity and safety of a new single dose live 
attenuated oral vaccine against typhoid fever in healthy paediatric subjects from Viet Nam.  The 
product, M01ZH09, contains a strain of S. typhi that has been rationally attenuated, by the 
introduction of two, independently attenuating, deletion mutations in its chromosome.  The clinical 
studies performed to date with M01ZH09 have assessed safety, tolerability and immunogenicity in 
adult subjects in the USA, UK and Viet Nam. Later in the clinical development of M01ZH09, Phase 
III field trials will be necessary in an area where typhoid fever is endemic.  Potential endemic areas 
for such a study exist in Viet Nam and Nepal.  Field trials of a typhoid vaccine will involve 
children, as children under 10 years of age make up a significant proportion of the population that 
experience typhoid disease.  The purpose of this study is to demonstrate immunogenicity and safety 
in a paediatric Vietnamese population prior to initiating field trials where it is anticipated that the 
youngest subjects that will be vaccinated will be 5 years of age. 
 
2.2 Investigational Product 
M01ZH09 is a live attenuated S. typhi oral vaccine, against typhoid fever, previously identified as 
MICRO-TY.  M01ZH09 consists of a freeze-dried formulation of the vaccine strain, S. typhi (Ty2 
aroC– ssaV–) ZH9, plus exc ipients, supplied in a single dose vial. 
S. typhi strain S. typhi (Ty2 aroC– ssaV–) ZH9 contains defined (independently attenuating) 
deletions in two genes, aroC and ssaV.  The aroC gene encodes chorismate synthase, an enzyme 
involved in the biosynthesis of aromatic compounds.  aro mutations are well described as being 
attenuating for Salmonella in humans, and the basis is presumed to be that two aromatic 
compounds, para-aminobenzoic acid and 2,3-dihydroxybenzoic acid are limiting for growth in 
mammalian tissue.  The ssaV gene is encoded on Salmonella Pathogenicity Island 2 (SPI-2).  SPI-2 
encodes a type III secretion system and ssaV is a structural gene encoding part of the secretion 
apparatus.  SPI-2 mutations are attenuating in mice, and there is evidence that this is because SPI-2 
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is required for survival and growth within macrophages, which normally mediate the systemic 
spread of the organism (Shea et al., 1999).  The rationale for inclusion of the ssaV deletion mutation 
is that it will prevent systemic spread of the vaccine strain in humans, and therefore prevent 
bacteraemias.  Bacteraemias have been recorded in subjects who have received attenuated 
Salmonella vaccines containing only aro deletions. 
S. typhi (Ty2 aroC– ssaV–) ZH9 is derived from the virulent S. typhi strain Ty2.  This strain has 
been used as a background strain for constructing candidate typhoid vaccines evaluated in 
volunteers previously.  The currently USA licensed live Salmonella vaccine is derived from this 
strain. 
 
2.3 Non-Clinical Summary 
The attenuation of S. typhi (Ty2 aroC– ssaV–) ZH9 has been demonstrated directly by comparing 
replication in human macrophage-like cells of S. typhi (Ty2 aroC– ssaV–) ZH9 with S. typhi (Ty2 
aroC–) DTY8, which harbours a single aroC mutation, in the presence and absence of aromatic 
compound supplements.  
Replication of S. typhi (Ty2 aroC– ) DTY8 strain in U937 macrophage- like cells was much lower in 
the absence of additional aromatic amino acids (1 round of replication within macrophages in a 48 
hour period compared to 4 to 5 rounds when aromatic amino acids were added).  Thus the aroC 
mutation reduces replication of S. typhi in macrophages, in agreement with a previous study (Lowe 
et al., 1999).  
In contrast, S. typhi (Ty2 aroC– ssaV–) ZH9, showed no increase in cell numbers, even in the 
presence of aromatic compound supplements, over the 48-hour period.  The ssaV mutation 
therefore completely prevents replication in human macrophage like cells for 48 hours. These 
results confirm the previous studies, demonstrating the role of SPI-2 genes in bacterial proliferation 
within macrophages (Ochman et al., 1996) and demonstrate the utility of mutations in SPI-2 as an 
attenuation strategy for Salmonella.  Emergent Product Development UK Ltd considers this to be a 
key safety study.  
S. typhimurium strains harbouring either a single aroC deletion mutation or deletion mutations in 
both aroC and ssaV have been used to demonstrate the additional utility of the ssaV mutation over 
that of the aroC mutation in immuno-compromised mice. 
Experiments in IFNg knock out mice demonstrated that SPI-2 mutants of Salmonella, including a 
strain carrying exactly the same mutation as the candidate vaccine strain  S. typhi (Ty2 aroC– ssaV–
) ZH9 were unable to kill immuno-compromised animals whereas attenuated strains containing only 
aro mutants did kill immuno-compromised mice.  The combination of an SPI-2 mutation such as 
ssaV with an aro mutation in a Salmonella vaccine candidate therefore provides additional safety 
assurance for use of these strains in humans. 
A single dose study designed to assess the potential toxicity of S. typhi (Ty2 aroC– ssaV–) ZH9 
when administered to CD-1 mice by oral gavage at doses of 5 x 107 and 5 x 109 colony forming 
units (CFU) showed no systemic toxicological changes.  There were no significant changes in 
bodyweight, food consumption, haematology, clinical chemistry, organ weights, macroscopic or 
microscopic pathology in the 15-day period following dosing.  Recovery of S. typhi (Ty2 aroC– 
ssaV–) ZH9 was demonstrated in mouse faeces in both treated groups from 1 to 5 days after dosing. 
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2.4 Clinical Summary 
Summary of Clinical Data to Date 
To date S. typhi (Ty2 aroC– ssaV–) ZH9 has been administered to over 100 healthy adult volunteers 
in four studies.  In the first study (Study MS01.01) 9 subjects (3 per cohort) received doses of 
either, 107, 108 or 109 CFU of a frozen formulation of the vaccine.  In the second study (Study 
MS01.03) 48 subjects (16 per cohort) received doses of 5 x 107, 5 x 108 or 5 x 109 CFU of a freeze-
dried formulation of the S. typhi (Ty2 aroC– ssaV–) ZH9 vaccine.  In the third study (Study 
MS01.04) 32 subjects received one dose of 5 x 109 CFU of the freeze-dried formulation and in the 
fourth study (MS01.07) a further 16 subjects received one dose of 5 x 109 CFU of the freeze-dried 
formulation.  These studies indicate that the vaccine is immunogenic with a good safety profile. 
Summary of Data from Study MS01.01 
Study MS01.01 was an open non-controlled, in-patient dose escalating exploratory study conducted 
under a Doctors and Dentists exemption certificate (DDX), designed to determine the safety and 
tolerability of three dose levels of the attenuated live Salmonella typhi strain S. typhi (Ty2 aroC– 
ssaV–) ZH9 (Hindle et al, 2002). Nine (3 cohorts of 3) healthy adult volunteers received a single 
oral dose of 107, 108 or 109 CFU of the vaccine strain. 
This study demonstrated that the candidate, live oral typhoid vaccine strain S. typhi (Ty2 aroC– 
ssaV–) ZH9 was well tolerated.  There was no evidence of systemic spread of the bacteria.  All 
blood and urine cultures remained negative in all subjects at all time-points examined.  Persistent 
shedding (defined as shedding beyond Day 7) in the stools was not observed in any of volunteers of 
the three dose groups.  The adverse events reported by single subjects that were potentially related 
to study medication were abdominal discomfort, headache, diarrhoea (more than 3 unformed stools 
in a 24-hour period), nausea and vomiting.  S. typhi (Ty2 aroC– ssaV–) ZH9 was determined to be 
immunogenic at doses of 107 to 109 CFU in human subjects. 
Summary of Data from Study MS01.03 
Study MS01.03 was a single dose, placebo controlled, double blind, dose-escalating study 
conducted under an Investigational New Drug (IND). The study was designed to determine the 
safety, tolerability and immunogenicity of three dose levels of M01ZH09 which consisted of a 
freeze dried formulation of the live attenuated vaccine strain S. typhi (Ty2 aroC– ssaV–) ZH9 and 
excipients.  A total of 60 healthy adult volunteers were recruited in 3 cohorts of 20.  In each cohort, 
16 subjects were randomised to receive vaccine and 4 to receive placebo.  The cohorts were dosed 
sequentially receiving doses of 5x107 CFU of S. typhi (Ty2 aroC– ssaV–) ZH9, 5x108 CFU of S. 
typhi (Ty2 aroC– ssaV–) ZH9, 5x109 CFU of S. typhi (Ty2 aroC– ssaV–) ZH9 or placebo.  Dose 
escalation proceeded only after a safety review group had determined that it was appropriate to 
escalate the dose. 
Safety Data (MS01.03) 
None of the blood cultures taken during the study was positive for S. typhi (Ty2 aroC– ssaV–) ZH9. 
Faecal shedding of S. typhi (Ty2 aroC– ssaV–) ZH9 did not continue beyond 6 days for any subject, 
at any of the dose levels. The number of subjects with faecal shedding of the vaccine strain 
increased with increasing dose level.   
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There were no serious adverse events (SAEs) related to study medication.  A total of three SAEs 
were reported, two in the 28-day period following dosing, both involved minor surgical procedures 
for pre-existing conditions.  The third SAE was reported in the six month follow up period when a 
subject was admitted to hospital for adjustment of medication for a pre-existing condition.   
Forty-six subjects reported adverse events affecting the gastrointestinal system including flatulence, 
abdominal pain or discomfort and nausea.  A total of 41 subjects reported adverse events of the 
nervous system; with the most frequently reported being headache.  Thirty-six subjects reported 
general disorders with fatigue being the commonest event in this category.  Thirty subjects reported 
adverse events related to the musculoskeletal system with musculoskeletal pain and myalgia being 
the commonest complaints.  The majority of adverse events were of mild severity although some 
subjects reported moderate abdominal pain; these were spread evenly across all dose groups.  
Adverse events that were reported as severe included headaches, which were reported by subjects in 
all groups that received the vaccine, infections (urinary tract and ear infections neither caused by the 
vaccine strain), hunger, and nasal congestion.  Eight subjects reported pyrexia (temperatures of 37.4 
– 38.7°C), with no evidence of a bacteraemia.  One case was not considered related to study 
medication.  Of the remaining 7 cases, 2 subjects were in the placebo group 2 were in the 5 x 108 
and 3 in the 5 x 109 CFU group.  Four of these events were of mild severity and were considered 
possibly related to study medication.  One subject in the 5 x 109 CFU dose group reported a body 
temperature of 38.3°C approximately 16 hours after receiving the dose of vaccine, the event was 
considered as severe and probably related to study medication.  A second subject in the 5 x 109 CFU 
group, had a swinging temperature up to 38.7 °C on study Days 10 and 11.  Ten subjects reported 
rigors/chills, 1 in the placebo group, 2 in the 5 x 107 CFU dose group, 4 in the 5 x 108 CFU dose 
group and 3 in the 5 x 109 CFU dose group.  Three of these subjects reported having pyrexia 
concurrent with their rigors/chills.  Only one of the rigors/chills was reported as being severe, 10 
days after dosing with 5 x 109 CFU, and this subject also experienced a pyrexia.  There was no 
statistically significant difference in the incidence of adverse events between subjects receiving the 
vaccine and those who received placebo and M01ZH09 was well tolerated by all of the subjects 
dosed.  
Immunogenicity (MS01.03) 
All three dose levels were shown to be immunogenic, with the highest dose being immunogenic in 
all subjects.  In both the 5 x 107 and 5 x 108 CFU dose groups 9 (56%) subjects in each group 
mounted an IgA immune response on Day 7 or an IgG response on Day 28.  This number increased 
to 16 (100%) in the 5 x 109 CFU dose group.  None of the subjects that received placebo mounted 
an immunological response against S. typhi (Ty2 aroC– ssaV–) ZH9. 
Summary of Data from Study MS01.04 
Study MS01.04 was a single centre, open, randomised, parallel group study conducted under an 
IND. The study was designed to determine the immunogenicity and safety of two different 
presentations of 5 x 109 CFU of M01ZH09 administered as a single oral dose to healthy volunteers.  
A total of 32 healthy adult volunteers were recruited to the study.  Sixteen subjects were 
randomised to receive vaccine presentation 1 and 16 to vaccine presentation 2.   
Subjects receiving vaccine presentation 1 consumed 100 mL of 2% (w/v) sodium bicarbonate 
solution between 5 and 20 minutes prior to receiving the vaccine administered in a further 50 mL of 
2% (w/v) sodium bicarbonate solution.  The solution was prepared using bottled water.  
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Subjects randomised to vaccine presentation 2, received the vaccine in 150 mL of a solution 
containing 1.75% (w/v) sodium bicarbonate, 1.1% (w/v) ascorbic acid and 0.02% (w/v) aspartame.  
The solution was prepared using tap water. 
All 32 subjects who entered the study received their dose of vaccine and 31 subjects completed the 
study.  One subject withdrew their consent and therefore did not complete the study. 
Safety Data (MS01.04) 
The majority of subjects (84%) in the study reported at least one post-vaccination adverse event.  A 
total of 15 (94%) of subjects that received M01ZH09 in presentation 1 reported 44 events.  In 
comparison a total of 12 (75%) subjects that received M01ZH09 in presentation 2, reported 51 
events.  The majority of the events were gastrointestinal or nervous system disorders. 
Gastrointestinal disorders were reported by 8 (50%) subjects in each presentation group.  The 
commonest events specific to the gastrointestinal system were loose stools, which were reported by 
4 and 2 subjects for presentations 1 and 2 respectively and abdominal pain, which were reported by 
3 and 1 subject(s) respectively.  Nervous system disorders were reported by 6 (38%) subjects in 
presentation 1 and by 10 (63%) subjects in presentation 2.  The commonest event specific to the 
nervous system was headache, which was reported by 6 and 9 subjects for presentations 1 and 2 
respectively.  Respiratory, thoracic and mediastinal disorders were reported by 3 (19%) subjects 
receiving presentation 1 and 5 (31%) subjects receiving presentation 2. 
There were no deaths or SAEs reported.  The majority of events were of mild or moderate severity 
with only 7 of the 95 events being reported as severe. 
There was little difference between the presentations in terms of the occurrence of adverse events. 
Immunogenicity Data (MS01.04) 
The majority of subjects showed an immune response following administration of M01ZH09. 
Fifteen subjects (94%) who received presentation 1 mounted an immune response as demonstrated 
by an increase in the number of antibody secreting cells (ASCs) to 4 or more and /or seroconversion 
of the subjects with the presence of IgG antibody specific to S. typhi LPS.    Fourteen subjects 
(93%) who received presentation 2 mounted an immune response.  Both groups had a statistically 
significant difference to an assumed response rate of 50%, (p£0.001; 95% CIs (69.8%, 99.8%) for 
presentation 1 and (68.1%, 99.8%) for presentation 2). 
For the IgG response, the proportion of subjects who had an immune response was higher for 
presentation 1 (13 subjects, 81%, 95% CI (54.4%, 96.0%)) than for presentation 2 (8 subjects, 53%, 
95% CI (26.6%, 78.7%)). 
For the IgA response, 14 subjects in both groups mounted an immune response but the proportion 
of subjects who had an immune response was lower for presentation 1 (14 subjects, 88%, 95% CI 
(61.7%, 98.4%)) than for presentation 2 (14 subjects, 93%, 95% CI (68.1%, 99.8%)) as one subject 
in presentation 2 did not attend the Day 7 visit to provide a blood sample. 
There was no evidence of a difference between the groups in the proportion of subjects mounting 
either an IGA or an IGG immune response (p=1.0; 95% CI    (-16.9%, 17.7%)). 
Similar results were seen for the IgA response alone (p=1.0; 95% CI (-26.4%, 14.7%)). 
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For the IgG response there were differences in the proportions of subjects showing an immune 
response although this difference was not statistically significant (p=0.1351; 95% CI (-3.8%, 
59.6%)). 
Overall the immunogenicity was comparable for both presentations and the safety profiles were 
similar.  Based on these data it seems appropriate to use presentation 2 in MS01.07 as it is prepared 
and administered in a more convenient way and also the total amount of bicarbonate consumed is 
lower (2.6g compared to 3g). 
Summary of Data from Study MS01.07 
Study MS01.07 was a single centre, placebo-controlled, single-blind, randomised, parallel group, 
single oral dose study. The study was designed to determine the immunogenicity and safety of 5 x 
109 CFU of M01ZH09 administered as a single oral dose to healthy adult volunteers of Vietnamese 
origin.  The study planned to recruit 28 subjects.  A total of 27 healthy adult volunteers were 
actually recruited to the study.  It was anticipated that 16 subjects would be randomised to receive 
vaccine and 12 subjects to receive placebo.  The actual number of subjects that received vaccine 
was 16 and the number that received placebo was 11. 
Subjects received either vaccine or placebo in 150 mL of a buffer solution containing 1.75% (w/v) 
sodium bicarbonate, 1.1% (w/v) ascorbic acid and 0.02% (w/v) aspartame.  The buffer solution was 
prepared using drinking water. 
All 27 subjects that entered the study received their dose of either vaccine or placebo and all 27 
completed the study.   
Safety Data (MS01.07) 
Nine (82%) of the subjects who received placebo reported a total of 14 adverse events and 8 (50%) 
of subjects that received M01ZH09 reported 23 adverse events.  The only events reported by 10% 
or more of subjects were diarrhoea, abdominal pain and headache.  There were no apparent 
differences between the placebo and active groups in the frequencies of these events.   
None of the subjects recorded a bacteraemia, a serious or a severe adverse event and none of the 
subjects withdrew due to an adverse event.  The majority of events were of mild severity with only 
5 events considered to be of moderate severity.  None of the adverse events reported required 
treatment or medication for the adverse event. 
None of the subjects recorded or reported a fever or had any clinically significant changes in 
laboratory parameters.   
None of the subjects experienced persistent faecal shedding of S. typhi (Ty2 aroC– ssaV–) ZH9.  
(Persistent faecal shedding was defined as shedding of S. typhi (Ty2 aroC– ssaV–) ZH9 beyond day 
7). 
Overall M01ZH09 appears to have been very well tolerated and to have a good safety profile in 
healthy adult Vietnamese subjects.  
Immunogenicity Data (MS01.07) 
Sera from blood were taken fortnightly until Day 28 and will be obtained 6 month post vaccination 
for the evaluation of IgG responses against S. typhi LPS, S.typhi flagellin and S.typhi Vi as assessed 
by the ELISA technique. Peripheral blood mononuclear cells (PBMC) were isolated from blood 
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collected on Days 0 and 7 and assayed, using the ELISPOT technique, for the presence of ASCs 
secreting IgA specific for S.typhi LPS. 
Subjects were considered to have had an immune response if they achieved a Day 7 result of = 4 
ASCs per 106 PBMC, secreting IgA specific for S. typhi LPS detected by ELISPOT assay, 
(assuming a Day 0 result of <4 ASCs per 106 PBMC), and/or undergo seroconversion for serum IgG 
to LPS.  Seroconversion for serum IgG to LPS is defined as a four-fold or greater increase in the 
serum IgG antibody on serial dilution by ELISA, to S. typhi LPS between Day 0 and Day 28. 
None of the subjects that received the placebo mounted an immunological response against S.typhi 
(Ty2 aroC¯ ssaV¯) ZH9.  11/15 subjects (73%) within the group receiving a single dose (5 x 109 
CFU) of M01ZH09 typhoid vaccine demonstrated an LPS specific IgA response between day 0 and 
day 7.  3/16 subjects (19%) demonstrated an LPS specific IgG response between day 0 and day 28.  
Overall 69% (11/16) of subjects within the group receiving a single dose (5 x 109 CFU) of S.typhi 
(Ty2 aroC¯ ssaV¯) ZH9 satisfied the primary immunogenicity endpoint of the MS01.07 study (ITT 
population). 
 
2.5 Rationale for Dose 
The purpose of this study is to investigate the safety and immunogenicity of the vaccine in a 
different age group to that tested to date.  To achieve this it is essential to use a dose that is known 
to be immunogenic.  In study MS01.03 the maximum dose administered (5 x 109 CFU) was 
immunogenic in all 16 subjects dosed.  The lower doses investigated in Study MS01.03 were 
immunogenic in approximately 50% of the subjects.  The safety profiles were similar for all groups; 
hence, at the doses investigated toxicity did not limit dosing.  In Study MS01.04, the dose studied (5 
x 109 CFU) was immunogenic in 29 of 32 subjects.   In Study MS01.07, the dose studied (5 x 109 
CFU) was immunogenic in 11 of 16 Vietnamese subjects.  There is precedent for using the same 
dosage of live typhoid vaccine in children as adults.  School children in the Vivotif (Ty21a) clinical 
trial in Chile received the same regimen as used for the licensed product in adults (Ferreccio et al., 
1989).  Moreover, Vivotif is licensed for use in the US; it is indicated for immunisation of adults 
and children greater then 6 years of age using the same immunisation schedule.  In line with other 
live vaccines, such as Stamaril (yellow fever) and Meruvax II (rubella), the same parenteral dose is 
given to children as it is to adults.  For these reasons it has been determined that the appropriate 
dose for this study is a nominal dose of 5 x 109 CFU of S. typhi (Ty2 aroC– ssaV–) ZH9.   
 
2.6 Study Population 
The study will recruit 150 healthy paediatric Vietnamese subjects.  Subjects will be of either gender 
and will be between 5 and 14 years of age, who are willing to take part, whose parents or guardians 
give written permission and who meet all the inclusion and exclusion criteria. 
At least 70% of the subjects in each group will be aged 5 to 10 years inclusive. 
 
2.7 Risks and Benefits 
The anticipated risks of the study are in line with the side effect profile seen to date with M01ZH09.  
The most likely adverse effects are flatulence, abdominal cramps/discomfort, loose/unformed 
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stools, headache, nausea, vomiting, chills/rigors, minor elevations in body temperature (up to 38oC) 
and mild muscle and joint pain in subjects receiving the active vaccine. 
For subjects receiving the active vaccine there is a theoretical risk of developing a mild typhoid- like 
condition.  Theoretically there is also a potential risk of subjects developing a clinically significant 
bacteraemia, or becoming a carrier of the Salmonella strain S. typhi (Ty2 aroC- ssaV-) ZH9, and 
while these outcomes are considered highly unlikely and have not been seen to date in the 
populations studied, both these conditions would require treatment with antibiotics (refer to Section 
6.6 for recommended antibiotic treatment). 
There is a potential risk of subjects developing allergic symptoms, such as rashes or anaphylaxis.  
There may also be other as yet unforeseen risks. 
The investigational product will be administered in a bicarbonate solution containing 1.75% (w/v) 
sodium bicarbonate, 1.1% (w/v) ascorbic acid and 0.02% (w/v) aspartame. Subjects aged 5 to 10 
years will receive the vaccine or placebo in 75 mL of bicarbonate solution.  Subjects aged 11 to 14 
years will receive the vaccine or placebo in 150 mL of bicarbonate solution.  The solution is 
prepared from effervescent bicarbonate tablets using drinking water.  The bicarbonate solution may 
induce some abdominal discomfort and/or cramping around the time of dosing. 
Subjects who have received 5 x 109 CFU of M01ZH09 have developed an immune response.  At 
present it is not known if the immune response generated by M01ZH09 is protective against 
infection from S. typhi.  There can be no assumed benefit for the subjects receiving M01ZH09 even 
if an immune response is detected; such a response cannot be assumed to be protective.  If any 
protection is obtained, the duration of any such protection is currently unknown. 
 
2.8 Study Treatment 
Subjects will receive a single dose of M01ZH09 administered orally.  The oral route of 
administration is the normal route of entry for S. typhi hence it is appropriate to administer the 
vaccine by the same route.  There will be 2 groups of subjects; 100 subjects will be randomised to 
receive a nominal dose of 5 x 109 CFU of M01ZH09 oral vaccine and 50 subjects will receive 
placebo.  M01ZH09 is supplied as a freeze-dried formulation of the vaccine strain, plus excipients, 
in single dose vials. The placebo is supplied as a freeze-dried formulation of vaccine excipients, in 
single dose vials. 
It is planned that a total of 100 subjects will receive the M01ZH09 vaccine in a bicarbonate solution 
containing 1.75% (w/v) sodium bicarbonate, 1.1% (w/v) ascorbic acid and 0.02% (w/v) aspartame.  
The solution is prepared from bicarbonate tablets using drinking water. 
It is planned that a total of 50 subjects will receive placebo, consisting of the vaccine excipients in a 
bicarbonate solution containing 1.75% (w/v) sodium bicarbonate, 1.1% (w/v) ascorbic acid and 
0.02% (w/v) aspartame.  The solution is prepared from bicarbonate tablets using drinking water. 
Subjects aged 5 to 10 years will receive the vaccine or placebo in 75 mL of bicarbonate solution.  
Subjects aged 11 to 14 years will receive the vaccine or placebo in 150 mL of bicarbonate solution 
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2.9 Compliance Statement 
This study is to be performed in compliance with this protocol, local and national guidelines and 
regulations and the following code of federal regulations; 
· 21CFR 50 subpart B – Informed Consent of Human Subjects 
· 21CFR54 – Financial Disclosure by Clinical Investigators 
· 21CFR312.60 – General Responsibilities of Investigators 
· 45CFR46 – Protection of Human Subjects 
· Current ICH Guideline for Good Clinical Practice 
Quality assurance systems and procedures will be implemented to assure the quality of every aspect 
of the study. 
MS01.08 V2 FINAL 17 January 2007 
 
 
Page 36 of 72 
 
3 STUDY PURPOSE, OBJECTIVES AND ENDPOINTS 
3.1 Purpose 
The purpose of the study is to determine the safety and immunogenicity of the oral vaccine 
M01ZH09 in healthy paediatric Vietnamese subjects.  The clinical studies performed to date with 
M01ZH09 have assessed safety, tolerability and immunogenicity in adult subjects in the USA, UK 
and Viet Nam.  Later in the clinical development of M01ZH09, Phase III field trials will be 
necessary in an area where typhoid fever is endemic.  Potential areas for such a study exist in Viet 
Nam and Nepal.  Field trials of a typhoid vaccine will involve children, as children under 10 years 
of age make up a significant proportion of the population that experience typhoid disease.  The 
purpose of this study is to demonstrate immunogenicity and safety in a paediatric Vietnamese 
population prior to initiating field trials where it is anticipated that the youngest subjects that will be 
vaccinated will be 5 years of age. 
 
3.2 Objective 
To evaluate the safety and immunogenicity of M01ZH09 typhoid vaccine (oral live S. typhi (Ty2 
aroC– ssaV–) ZH9) at a nominal dose of 5 x 109 CFU in healthy paediatric subjects from Viet Nam.   
 
3.3 Safety Endpoints 
3.3.1 Primary 
The proportion of subjects reporting SAEs attributed to the study medication. 
3.3.2 Secondary 
The proportion of subjects; 
· Experiencing an elevated body temperature, of 38.5°C or greater, in the 14 days following 
dosing, attributed to study medication. 
· Demonstrating persistent (after Day 7) faecal shedding of S. typhi (Ty2 aroC– ssaV–) ZH9. 
· Withdrawn from the study due to adverse events, including bacteraemia, attributed to study 
medication. 
· With clinically significant changes in laboratory parameters, from Day 0 to any time post 
dosing, which are attributed to study medication. 
 
3.4 Immunogenicity Endpoints 
Assessment of the immune response will be made by determining the proportion of subjects who; 
· Develop a positive immune response* to S. typhi LPS as assessed by an increase in S. typhi LPS 
specific IgG at either Day 14 or Day 28. 
· Develop a positive immune response* to S. typhi LPS as assessed by an increase S. typhi LPS 
specific IgA at either Day 7 or Day 14. 
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· At Day 7, have = 4 ASCs per 106 PBMC, secreting IgA specific for S. typhi LPS detected by 
ELISPOT assay  
 
*The definition of a ‘positive immune response’ will be determined following the completion of 
assay development. 
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4 STUDY DESIGN 
4.1 Summary of Study Design 
This is a placebo-controlled, parallel group, randomised, single-blind, single centre study.  Subjects 
will be randomly allocated to one of two treatment groups and will receive either a single dose of 
M01ZH09 at a nominal dose of 5 x 109 CFU or placebo.  A total of 100 subjects will take 
M01ZH09 and 50 will take placebo. 
 
4.2 Rationale for Study Design 
The study will be conducted following the principles of a double blind study, as per the accepted 
norm as the gold standard for these types of study.  While this is the intent, perfect blinding cannot 
be guaranteed for a number of reasons (see Section 4.5, Blinding).  The placebo serves as a measure 
of background adverse events and wild-type typhi immunogenicity markers.  Allowing more 
children in the range 5-10 years of age will increase the data available in the age group to likely be 
employed for Phase III field trials. 
 
4.3 Study Population 
The study will recruit 150 healthy paediatric Vietnamese subjects.  Subjects will be of either gender 
and will be between 5 and 14 years of age, inclusive, who are willing to take part, whose parents or 
guardians give written permission and who meet all the inclusion and exclusion criteria. 
At least 70% of the subjects in each group will be aged 5 to 10 years inclusive. 
 
4.4 Rationale for Dose 
The purpose of this study is to investigate the safety and immunogenicity of the vaccine in a 
different age group to that tested to date.  To achieve this it is essential to use a dose that is known 
to be immunogenic. In previous studies, the maximum dose administered (5 x 109 CFU) has been 
shown to be immunogenic.  Lower doses investigated in previous studies were immunogenic in 
approximately 50% of the subjects.  The safety profiles have been similar for all doses 
administered; hence, at the doses investigated, toxicity did not limit dosing.  There is precedent for 
using the same dosage of live typhoid vaccine in children as adults.  School children in the Vivotif 
(Ty21a) clinical trial in Chile received the same regimen as used for the licensed product in adults 
(Ferreccio et al., 1989).  Moreover, Vivotif is licensed for use in the USA; it is indicated for 
immunisation of adults and children greater than 6 years of age using the same immunisation 
schedule.  In line with other live vaccines, such as Stamaril (yellow fever) and Meruvax II (rubella), 
the same parenteral dose is given to children as it is to adults.  For these reasons it has been 
determined that the appropriate dose for this study is a nominal dose of 5 x 109 CFU of S. typhi 
(Ty2 aroC– ssaV–) ZH9. 
 
4.5 Blinding 
Active vaccine and matching placebo will be packaged identically but with a unique sequential 
number. This number will enable identification of the contents in case of emergency when used 
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with the randomisation code break. Preparation of both active and placebo doses will be identical. 
Hence the investigator and his staff will be essentially blinded in that knowledge of the product 
supplied to the subjects will remain unknown.  However, three areas remain where unintentional 
unblinding may occur. 
1. The placebo and M01ZH09 solutions differ slightly in taste and aroma.  Individual subjects will 
be unaware of any differences in dosing solutions and consequently will be blinded to their 
treatment in the study.  The investigator may detect a difference between the products based on 
the aroma.  A double observer design would reduce this risk but personnel with paediatric 
expertise at the site are limited, and a double observer design is unlikely to be possible. 
2. Subjects will have stool samples taken for culturing and it is anticipated that subjects receiving 
M01ZH09 will shed S. typhi (Ty2 aroC– ssaV–) ZH9 in their stools.  Results from the stool 
microbiology will therefore potentially unblind the investigator.  It is intended to request that 
the Investigator does not review these microbiology reports for at least the first 14 days post 
dosing. 
3. Subjects will have blood samples taken for the determination of IgG and IgA specific to 
S. typhi.  Subjects that develop an immune response will clearly be identifiable as having 
received M01ZH09.  For this reason it is intended to request that the Investigator does not 
review these immunology results for at least the first 14 days post dosing. 
 
4.6 Study Treatments 
The vaccine and placebo will be supplied in labelled single dose glass vials, in labelled boxes, to the 
pharmacy at the study site.  Each vial will contain a nominal dose of 5 x 109 CFU S. typhi (Ty2 
aroC– ssaV–) ZH9 or placebo.  M01ZH09 is supplied as a freeze-dried formulation of the vaccine 
strain, plus excipients, in single dose vials (see Section 6.1).  The placebo contains only the 
excipients.  Subjects will receive one single oral dose of 5 x 109 CFU S. typhi (Ty2 aroC– ssaV–) 
ZH9 or placebo.   
Effervescent bicarbonate tablets containing 2.6 g sodium bicarbonate, 1.65 g ascorbic acid and 
30 mg aspartame will be supplied.  The bicarbonate tablets will be dissolved in drinking water.  
Once the tablet has completely dissolved, the vaccine will be added to this solution. 
The pharmacist must confirm receipt of study medication in writing.  Emergent Product 
Development UK Ltd or its authorised agent will retain samples of study medication. 
 
4.7 Duration of Subject Participation 
Each subject’s participation in the study will be for up to 28 days during the screening period plus 
28 days following the administration of the investigational medicinal product (IMP), making a total 
of 56 days.  Recruitment of 150 subjects at the study site is expected to take approximately six 
months.   
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4.8 Stopping Rules 
4.8.1 Study as a Whole 
Emergent Product Development UK Ltd or the Investigator may decide to stop the study or part of 
the study at any time.  If the study is prematurely terminated or suspended, the Investigator should 
promptly inform the subjects and ensure appropriate therapy and follow-up. Furthermore, the 
Investigator should promptly inform the Ethics Committee and provide a detailed written 
explanation. The pertinent regulatory authorities must be informed according to national 
regulations. 
Should there be any serious AEs which are both unexpected and at least possibly related to the IMP 
following vaccination, there will be a suspension of dosing, a full review of the safety data and the 
study may be stopped. 
If, following dosing with IMP, subjects experience signs and symptoms as discussed below (See 
Table 1), dosing of further subjects will be suspended until a full review of the safety and laboratory 
data has been completed by the Investigator and the sponsor’s Medical Monitor.  The continuation 
of dosing will be dependent upon the findings of the review.   
 
Table 1: Rules for suspension of dosing 
 Events that would trigger a suspension of dosing 
 Moderate  Severe   
Gastrointestinal 
symptoms* 
30% of, or 6 subjects, 
dosed, whichever is the 
greater number of 
subjects, with moderate 
vomiting or diarrhoea. 
10% of, or 2 subjects, 
dosed, whichever is the 
greater number of 
subjects, with severe 
nausea, vomiting or 
diarrhoea. 
 
Systemic 
reactions  
30% of, or 6 subjects, 
dosed, whichever is the 
greater number of 
subjects, with moderate 
fever (= 38.5°C). 
10% of, or 2 subjects, 
dosed, whichever is the 
greater number of 
subjects with severe 
fever (= 39.5°C). 
1 subject with a 
positive blood culture 
for a S. typhi strain. 
Laboratory 
values** 
30% of, or 6 subjects, 
dosed, whichever is the 
greater number of 
subjects with moderate 
abnormalities. 
10% of, or 2 subjects, 
dosed, whichever is the 
greater number of 
subjects with severe 
abnormalities. 
 
Other Adverse 
Reactions  
 10% of, or 2 subjects, 
dosed, whichever is the 
greater number of 
subjects with a related 
possibly or probably 
(Section 8.1.4)) SAE. 
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* See Table 2 
** See Table 3 
 
Table 2: Definition of severity for gastrointestinal symptoms  
Symptom Moderate Severe  
Nausea Affects the subject’s normal 
daily activities. 
Prevents the subject’s normal 
daily activities or requires 
confinement to bed. 
Vomiting* More than 4 episodes in a 24-
hour period but no evidence of 
clinically significant 
dehydration. 
More than 6 episodes in a 24-
hour period or evidence of 
significant dehydration as a 
result of the vomiting. 
Diarrhoea* More than 4 unformed stools in 
a 24-hour period but no 
evidence of clinically 
significant dehydration. 
More than 6 unformed stools in 
a 24-hour period or evidence of 
significant dehydration as a 
result of the diarrhoea. 
 
* If the number of episodes are not reached but hospital admission is required, the event will still be 
classified as severe, as well as classifying as a Serious Adverse Event. 
 
Table 3: Definition of severity for laboratory value abnormalities 
Laboratory test Moderate Severe  
WBC increase = 15 to 20 x 109/L > 20 x 109/L 
WBC decrease < 2.5 to 1.5 x 109/L < 1.5 x 109/L 
Liver function tests  
(AST and ALT) 
2.5 to 3.5 x ULN* > 3.5 x ULN* 
 
* ULN = Upper Limit of Normal 
In the event of a salmonella bacteraemia, dosing will be suspended until it has been determined 
whether the strain responsible for the bacteraemia is S. typhi (Ty2 aroC– ssaV–) ZH9.  If it is 
determined that the bacteraemia should be attributed to S. typhi (Ty2 aroC– ssaV–) ZH9 or the 
vaccine strain cannot be ruled out as the causative agent, dosing will be suspended and an SAE 
report will be provided to the FDA and other relevant regulatory authorities. 
Other signs and symptoms may also lead to suspension of dosing or other changes in the intended 
protocol pending review of the safety data and culture results. 
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4.8.2 Individual Subjects 
If a subject wishes to leave the study at any time, or if either of the subject’s parents or guardians 
withdraw their permission, the subject will be permitted to leave the study without any penalty.  The 
collection of safety data is important for the safety of the individual subject and therefore, subjects 
who withdraw will be encouraged to monitor their temperature and adverse events and return for 
safety follow-up and the collection of samples for reasons of safety.  It will be stressed to the 
subject and his/her parents or guardians that if the subject becomes unwell they should, at a 
minimum, contact the investigative site and preferably visit the investigative site to ensure the 
vaccine has not caused any adverse events. 
 
4.9 Randomisation Codes and Breaking the Code  
Subjects will be allocated a ‘Screening Number’ on entry into the study (signature of the written 
permission document). This number, together with their initials will be used to identify them until 
they are deemed eligible to receive study treatment at Visit 1. 
At Visit 1, all subjects eligible to receive study treatment will be allocated a unique subject number 
(this number will be recorded in the Visit 1CRF together with the Screening Number; at subsequent 
visits, the subject will be identified by this number and their initials only). This number will be 
allocated strictly sequentially  (within each age-group cohort) in accordance with the randomisation 
schedule.  The randomisation schedule will determine if a subject receives vaccine or placebo.  The 
vials of IMP will be provided to the study site pre labelled with subject numbers. 
Code break will be provided to the Investigator.  The code for a particular subject can be broken in 
a medical emergency if knowing the identity of the treatment allocation would influence the 
treatment of the subject.  Whenever a code is broken, the person breaking the code must record the 
time, date and reason as well as their initials in the source documents. 
If the site needs to break the code, the sponsor should, if possible, be contacted prior to breaking the 
code.  In all cases, the Study Monitor must be notified within 24 hours after the code has been 
broken. 
All code break (whether broken or not) must be kept throughout the study period.  Codes will be 
checked for integrity and collected by the Study Monitor at study site closure. 
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5 SELECTION AND WITHDRAWAL OF SUBJECTS 
5.1 Inclusion Criteria 
Subjects must satisfy the following criteria 
1. Healthy paediatric subjects aged 5 to 14 years inclusive, of Vietnamese origin, who are able and 
willing to take part in the trial and whose parents or guardians give written permission for their 
child’s participation, following a detailed explanation of the study. 
2. Subjects who will be available for the duration of the study and available for scheduled and 
potential additional visits. 
 
5.2 Exclusion Criteria 
Subjects meeting any of the following criteria must be excluded from the study 
1. Subjects with any clinically significant medical or psychiatric condition or clinically significant 
abnormal serum biochemistry or haematology results that, in the opinion of the Investigator, 
preclude participation in the study. 
2. Subjects whose body weight is under 17kg (5-10 year olds), or under 27kg (11-14 year olds) 
3. Female subjects who are pregnant (confirmed with urinary pregnancy test) or breast- feeding, or 
of childbearing potential and unwilling to use a reliable method of contraception (oral 
contraceptives, barrier method with spermicidal preparation or abstinence) throughout the study 
period.   
4. Subjects who have a known hypersensitivity to two or more of the following antibiotics; 
ciprofloxacin, azithromycin or trimethoprim-sulfamethoxazole or have used 
antibiotics/antibacterials within 14 days prior to administration of study medication.   
5. Subjects who have a known hypersensitivity to any component of the vaccine or bicarbonate 
solution used in this study, including subjects with phenylketonuria or those who have 
experienced anaphylactic shock after any vaccination. 
6. Subjects who received Vivotif, either as a licensed or investigational product, in the last 10 
years or any other vaccine against S. typhi, whether licensed or investigational, in the last 5 
years, or who have ever suffered from typhoid fever.   
7. Subjects with direct contact with patients in special care units or immuno-compromised 
individuals. 
8. Subjects who have a positive bacterial culture of their faecal sample, obtained at the screening 
visit, for any Salmonella species. 
9. Subjects with a known impairment of immune function including acquired immune deficiency 
syndrome or those receiving (or having received in the 6 months prior to screening) cytotoxic 
drugs, immunosuppressive therapy (including systemic corticosteroids). 
10. Subjects who are HIV positive or have family members who are HIV positive.  (‘Family 
members’ includes immediate and extended family living in the same residential unit, or 
relations with whom the subject has regular and frequent contact). 
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11. Subjects with a significant acute febrile illness (body temperature of 38.0°C or more) at time of 
dosing.  
12. Subjects who have chronic diseases: Chronic diseases will include all autoimmune and immuno-
compromising conditions and any other chronic condition which, at the judgement of the 
Investigator, may put the subject at higher risk of side effects from the study vaccine.  
Conditions in the latter category might include unexplained anaemia, hepato-biliary disease, 
uncontrolled hypertension, subjects with prosthetic joints or heart valves, etc. 
13. Subjects with a current problem, based on history, of substance abuse or with a history of 
substance abuse that, in the opinion of the investigator, might interfere with participation in the 
study. 
14. Subjects who are currently involved in a clinical study, have taken an investigational drug or 
have received investigational or licensed vaccines in the 4 weeks before screening, or anticipate 
receiving a vaccine, other than study medication, during the first 4 weeks, post vaccination, of 
the study. 
Subjects exc luded for medical reasons will be referred to appropriate medical care services or 
counselling. 
 
5.3 Withdrawal Criteria 
Emergent Product Development UK Ltd or the Investigator may decide to stop the study or part of 
the study at any time.  If a study is prematurely terminated or suspended, the Investigator should 
promptly inform the subjects and ensure appropriate therapy and follow-up.  Furthermore, the 
Investigator should promptly inform the Ethics Committee and provide a detailed written 
explanation.  The pertinent regulatory authorities must be informed according to the national 
regulations. 
A subject may be withdrawn from the study at the discretion of the Investigator or the Sponsor, if 
judged non-compliant with study procedures or due to safety concerns. 
A subject must be withdrawn if any of the following apply: 
· The wish of the subject or either of his/her parents or guardians 
· Intolerable adverse event(s) 
· Clinically significant abnormal laboratory findings (which in the opinion of the Investigator 
and/or Sponsor precludes further participation in the study) 
· Non-compliance, (subject does not attend a minimum of 3 visits post dosing)  
· Use of treatments not permitted during the study (see section 6.6) 
· Investigator's decision that withdrawal from further partic ipation would be in the subject's best 
interest. 
· Pregnancy.  Any subject who becomes pregnant will be followed up to determine the outcome 
of the pregnancy.  The Investigator will be required to inform Emergent Product Development 
UK Ltd of a subject's pregnancy and the estimated date of delivery.  Emergent Product 
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Development UK Ltd will follow up with the Investigator around the estimated time of delivery 
to determine the outcome of the pregnancy. 
This is a single dose study; therefore subjects withdrawing after dosing would not be scheduled to 
receive any additional medication.  Blood draws for immunogenicity assessments would be 
discontinued, although safety assessments would be continued.  The collection of safety data is 
critically important and therefore subjects will be encouraged to return for the collection of samples 
for safety, whether they have been withdrawn for reasons of safety, have withdrawn their assent or 
have had their parental permission withdrawn.  As many safety samples as possible will be 
collected. 
 
5.4 Subject Replacement 
There will be no replacement of subjects who have received study medication.  Subjects who have 
permission and assent forms signed but withdraw before receipt of study medication will be 
replaced. 
 
5.5 Follow -up of Withdrawn Subjects 
If a subject withdraws from the study before the final visit then, if possible, all the Day 28 
assessments will be completed.  If the subject cannot attend for a final assessment then as a 
minimum, the End of Study Form must be completed.  If a subject withdraws due to an adverse 
event then the subject must be followed until the event ends or stabilises. 
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6 TREATMENT OF SUBJECTS 
6.1 Study Products 
Subjects will receive a single oral dose of vaccine or placebo.  The oral route of administration is 
the normal route of entry for S. typhi hence it is appropriate to administer the vaccine by the same 
route.  M01ZH09 is supplied as a freeze-dried formulation of the vaccine strain, plus excipients, in 
single dose vials. The excipients are shown in Table 4 below; 
Table 4: Excipients included in the single dose vials 
xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxx xxxxxx 
xxxxxxx xxxxxxxxxx 
xxxx xxxxxxxxxxxxxxx 
xxxxx xxxxxxxxxxx 
xxxxxxxxxxxx xxxxxxxxxxxxxxx 
xxxxxxxxxxxx xxxxxxxxxxx 
xxxxxxx xxxxxxxxxx 
 
There will be two groups; 100 subjects will be randomised to receive a nominal dose of 5 x 109 
CFU of M01ZH09 and 50 subjects will be randomised to receive placebo. 
Group 1.  Active, consisting of 5 x 109 CFU of M01ZH09 vaccine strain S. typhi (Ty2 aroC– ssaV–) 
ZH9 administered in a bicarbonate solution. 
Group 2.  Placebo, consisting of the vaccine excipients administered in a bicarbonate solution. 
The bicarbonate solution is made from an effervescent bicarbonate tablet containing 2.6 g sodium 
bicarbonate, 1.65 g ascorbic acid and 30 mg aspartame.  Each bicarbonate tablet will be dissolved in 
150 mL of drinking water.  The vaccine or placebo will be dissolved in the appropriate volume of 
this solution containing 1.75% (w/v) sodium bicarbonate, 1.1% (w/v) ascorbic acid and 0.02% 
(w/v) aspartame. 
Subjects aged 5 to 10 years will receive the vaccine or placebo in 75 mL of bicarbonate solution.  
Subjects aged 11 to 14 years will receive the vaccine or placebo in 150 mL of bicarbonate solution. 
 
6.2 Method of Administration of Each Dose 
The method for the reconstitution and administration of the vaccine will be detailed in a separate 
document provided to the Pharmacist and Investigator. 
Subjects will fast for at least 2 hours prior to taking the dose of medication and for 90 minutes after 
dosing (nothing to eat or drink, with the exception of water).  The subject will remain at the 
Investigative site, under observation, for at least 90 minutes following dosing. 
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6.3 Packaging and Labelling of Study Products 
Vials of IMP and bicarbonate tablets will be provided to the study site in cartons. One carton will 
contain one vial and one bicarbonate tablet. 
Each glass vial will be labelled with the following information as a minimum: 
Study Number: MS01.08 
Subject Number: 
M01ZH09 oral typhoid vaccine or placebo  
Caution: New Drug - Limited by Law to investigational use  
FOR ORAL ADMINISTRATION ONLY 
Keep refrigerated at 2°C to 8°C. DO NOT FREEZE 
Packaging reference number: 
Emergent Product Development UK Ltd, Berkshire RG41 5TU, UK 
 
Each tablet will be labelled with the following information as a minimum: 
Study Number: MS01.08 
Subject Number: 
Bicarbonate tablet for live attenuated vaccine (contains 2.6 g sodium bicarbonate, 1.65 g ascorbic 
acid and 30 mg aspartame) 
Caution: New Drug - Limited by Law to investigational use  
For oral use dissolved in water in accordance with the pharmacy instructions. 
Not to be swallowed directly. 
Store between 2°C and 27°C 
Lot number: 
Packaging reference number: 
Emergent Product Development UK Ltd, Berkshire RG41 5TU, UK 
 
The cartons will be sealed with tamper evident seals. The labels will contain as a minimum: 
Study Number: MS01.08 
Subject Number 
M01ZH09 oral typhoid vaccine or placebo, plus bicarbonate tablet 
Caution: New Drug - Limited by Law to investigational use 
FOR ORAL ADMINISTRATION ONLY 
Keep refrigerated at 2°C to 8°C. DO NOT FREEZE 
Lot / Packaging reference number: 
Sponsor: Emergent Product Development UK Ltd, Berkshire RG41 5TU, UK 
Investigator: Dr Hien, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam 
 
6.4 Storage and Drug Accountability of Study Products 
Vials of study medication must be kept refrigerated at 2°C to 8°C.  
The responsible pharmacist will maintain a Medication Accountability Log.  This will include the 
date, description and quantity of study medication received at the study site, as well as a record of 
when and to whom it was dispensed.   
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All unused supplies will be retained at site until Emergent Product Development UK Ltd gives 
instructions for their return or disposal.   
No study products may be dispensed to any person not enrolled in the study or used for purposes 
other than those described in this protocol. 
 
6.5 Other Materials 
Emergent Product Development UK Ltd will provide syringes for use during reconstitution of the 
vaccine, and dosing containers. 
 
6.6 Concomitant Medication 
The use of all medication including ‘over the counter’ and herbal products taken in the 4 weeks 
prior to screening and during the course of the study, up to Day 28, must be detailed in the case 
report form (CRF). Subjects are to try to avoid all antibiotic/antibacterial use for 14 days before and 
after dosing.  Should a subject require antibiotics he/she must inform the Investigator and may be 
withdrawn from the study depending on the timing in relation to the vaccination or have their data 
excluded from the PP analysis. Subjects must not receive any vaccine other than M01ZH09 during 
the four weeks, post dose, of the study. 
Oral contraception is allowed under the protocol.  However, should a female subject using oral 
contraception develop diarrhoea or require antibiotic therapy she will be requested to use additional 
barrier methods of contraception in combination with a spermicidal preparation. 
If a subject has  
· a single positive blood culture, or 
· a positive stool culture for S. typhi at any time after Day 7 
he/she must be treated with antibiotics.  The first line antibiotic will be ciprofloxacin 20 mg/kg 
twice daily, taken orally for 10 days.  The second line antibiotic will be azithromycin.  The dose of 
azithromycin is dependent upon the age of the subject.  Subjects aged 5 to 7 years should receive 5 
mL (200 mg) orally once daily for 7 days, subjects aged 8 to 11 years should receive 7.5 mL (300 
mg) orally  once daily for 7 days and subjects 11 to 14 years should receive 10 mL (400 mg) orally  
once daily for 7 days.  The third line antibiotic is trimethoprim 40 mg/sulfamethoxazole 200 mg per 
5 mL of suspension twice daily, 10 mL taken orally for 10 days. In all cases antibiotic therapy will 
be initiated as soon as the culture results are known. 
Any subject who returns for unscheduled visits after Day 14 and has positive blood or stool cultures 
for S. typhi will be treated as a potential carrier and treated with antibiotics and followed up until 
the infection is clear.  Antibiotics will be administered as outlined above at the discretion of the 
Investigator.  The duration of treatment may be up to 28 days to ensure the infection is clear. 
The vaccine strain has been shown to be sensitive to ciprofloxacin, azithromycin and 
trimethoprim/sulphamethoxazole.  Ciprofloxacin has been shown to be the treatment of choice for 
chronic carriers of wild type S. typhi. 
Anti-pyretic medications (for example, aspirin, ibuprofen, naproxen sodium) should not be taken 
for minor aches/pains or injuries as such medication may mask a fever.  Paracetamol is an 
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appropriate concomitant medication for these purposes.  Should a subject experience a fever (body 
temperature = 38.5°C) it is important that he/she contact the investigative site and visit to be 
assessed.  Subjects or their parents/guardians should not initiate anti-pyretic medication unless 
instructed to do so by the Investigator.  Anti-pyretics may be administered under the direction of the 
Investigator for the management of a diagnosed fever. 
 
6.7 Compliance 
The study staff will administer the study medication and observe the subjects’ compliance. 
 
6.8 Visits and Procedures 
6.8.1 Screening period (Day –28 to Day –1) 
The parents or guardians of all subjects will provide written permission before any study related 
procedure is carried out.  Where appropriate, with regard to age and understanding, the subject will 
be asked to sign an assent form indicating their willingness to take part in the study. After written 
permission has been obtained, the subject will be allocated a ‘Screening Number’ which will be 
used, together with his/her initials as their unique identifier until dosing at Visit 1. The following 
will be recorded/performed: 
 
· Demographic data 
· Medical history, including any allergies, and vaccination history 
· Prior concomitant medications (in previous 4 weeks before screening), particularly antibiotic 
use and including herbal and over the counter medications 
· Physical examination including height, weight and vital signs (blood pressure, temperature and 
pulse) and an examination for any signs of splenomegaly. 
· Draw blood for: 
o Serum biochemistry and haematology (Section 7.2.1)  
o HIV test 
· Obtain urine sample for: 
o Urine pregnancy test (females of 11 years and older only) 
o Dipstick test, and if the dipstick is positive for leucocyte esterase and nitrites, a 
separate sample will be sent for microscopy, culture and sensitivity 
· Obtain stool sample for culture for Salmonella spp. 
· Make an appointment for suitable subjects to attend for Visit 1 (randomisation and 
administration of the study medication) within the next 4 weeks. Instruct subject to bring a stool 
sample to the next visit. 
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6.8.2 Visit 1: Day of Dosing/ Day 0 
This visit should take place within 28 days of the screening visit, following receipt of the full 
laboratory results.  After the laboratory results have been reviewed, those subjects who continue to 
meet the inclusion criteria, and do not meet any of the criteria for exclusion, will continue in the 
study.  The following tasks will be performed: 
 
· Collect stool sample subject has brought to clinic.  (Note: This sample will not be cultured prior 
to dosing but if it is subsequently shown to be positive for any Salmonella strain the data from 
the subject will be excluded from the PP analysis). 
· Review the inclusion and exclusion criteria for continued study eligibility 
· Review medical history and record any changes since screening 
· Enquire about and record any adverse events since the last visit (see Section 6.8.9) to include an 
examination for any signs of splenomegaly 
· Enquire about and record any changes in concomitant medication since screening 
If the subject has received antibiotic therapy within 14 days of this visit, arrange for the 
subject to return for dosing if this is possible within 28 days of the screening visit. If not, 
please withdraw the subject from the study. 
Subjects who are withdrawn at Visit 1, under these circumstances and cannot be dosed within 
28 days of the Screening Visit may be re -screened. Under these circumstances the subject 
must be re-consented. 
If the subject remains eligible: 
· Determine and record vital signs (blood pressure, temperature and pulse) 
If oral temperature is 38°C or more, arrange for the subject to return for dosing if this is 
possible within 28 days of the screening visit. If not, please withdraw the subject from the 
study. 
Subjects who are withdrawn at Visit 1, under these circumstances and cannot be dosed within 
28 days of the Screening Visit may be re -screened. Under these circumstances the subject 
must be re-consented. 
· Obtain urine sample for: 
o Urine pregnancy test (females aged 11 years and older only) 
o Dipstick test, and if the dipstick is positive for leucocyte esterase and nitrites, a 
separate sample will be sent for microscopy, culture and sensitivity 
· If the subject remains eligible, allocate the next available  age-group specific Subject Number to 
the subject and enter this into the Visit 1 header of the CRF and the associated medication pack 
bearing this ‘Subject Number’. 
· Draw blood for: 
o Serum biochemistry and haematology 
o Serum IgG (ELISA assay)  
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o Serum IgA (ELISA assay)  
o Determining the number of ASC secreting IgA (ELISPOT assay; only for subjects 
aged at least 11 years and weighing at least 27 kg) 
· After ensuring that the subject has fasted for at least 2 hours, administer the dose of study 
medication (if the subject vomits within 1 hour of administration then he/she will need to 
receive a repeat dose). 
· Record pulse and blood pressure at 30, 60 and 90 minutes after dosing 
· Subjects will remain at the study site for at least 90 minutes following administration of study 
medication so that any adverse events may be recorded. 
· Subjects must not eat or drink (with the exception of water) for 90 minutes following 
vaccination 
· Issue a digital thermometer for recording body temperature orally. Subjects and their 
parents/guardians will be instructed to take body temperature readings each day in the morning 
when they get up and in the evening when they go to bed and to record the measurement in the 
Diary Card. 
· Issue a Diary Card and instruct the subject and their parents/guardians on its completion 
(Section 7.2.4) 
· Make an appointment for Visit 2/ Day 1 and instruct the subject to bring a stool sample to the 
visit. 
 
6.8.3 Visit 2: Day 1 
The subject will return to the clinic approximately 24 hours after dosing, where the following 
assessments will be completed: 
· Collect the stool sample that the subject has brought to the clinic for culture of vaccine strain S. 
typhi (Ty2 aroC– ssaV–) ZH9 
· Determine and record vital signs (blood pressure, temperature and pulse) 
· Review Diary Cards and summarise data in CRF 
· Enquire about and record any adverse events since the last visit (see Section 6.8.9) to include an 
examination for any signs of splenomegaly 
· Enquire about and record any changes in concomitant medication since the last visit 
· Make an appointment for Study Day 2 and instruct the subject to bring a stool sample to the 
visit 
 
6.8.4 Visits 3, 4, 5, 6 and 7: Days 2, 3, 4, 5 and 6 
The subject will return to the clinic where the following assessments will be completed: 
· Collect the stool sample that the subject has brought to clinic for culture of vaccine strain S. 
typhi (Ty2 aroC– ssaV–) ZH9 
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· Determine and record vital signs (blood pressure, temperature and pulse) 
· Review Diary Cards and summarise data in CRF 
· Enquire about and record any adverse events since the last visit (see Section 6.8.9) to include an 
examination for any signs of splenomegaly 
· Enquire about and record any changes in concomitant medication since the last visit 
· Make an appointment for a clinic visit on the following day and instruct the subject to bring a 
stool sample to the visit 
 
6.8.5 Visit 8: Day 7 
The subject will return to the clinic 7 days after vaccination, where the following assessments will 
be completed: 
· Collect the stool sample that the subject has brought to clinic for culture of vaccine strain S. 
typhi (Ty2 aroC– ssaV–) ZH9 
· Determine and record vital signs (blood pressure, temperature and pulse) 
· Review Diary Cards and summarise data in CRF. 
· Enquire about and record any adverse events since the last visit (see Section 6.8.9) to include an 
examination for any signs of splenomegaly 
· Enquire about and record any changes in concomitant medication since the last visit 
· Draw blood for:  
o Serum biochemistry and haematology 
o Serum IgA (ELISA assay) 
o Determining the number of ASC secreting IgA (ELISPOT assay; only for subjects 
aged at least 11 years and weighing at least 27 kg) 
· Obtain urine sample for: 
o Dipstick test, and if the dipstick is positive for leucocyte esterase and nitrites, a 
separate sample will be sent for microscopy, culture and sensitivity and also to 
determine if vaccine strain S. typhi (Ty2 aroC– ssaV–) ZH9 is present 
· Make an appointment for Study Day 8 and instruct the subject to bring a stool sample to the 
visit 
 
6.8.6 Visit 9, 10, 11, 12, 13 and 14: Days 8, 9, 10, 11, 12 and 13 
The subject will return to the clinic where the following assessments will be completed: 
· Collect the stool sample that the subject has brought to clinic for culture of vaccine strain S. 
typhi (Ty2 aroC– ssaV–) ZH9 
· Determine and record vital signs (blood pressure, temperature and pulse) 
· Review Diary Cards and summarise data in CRF. 
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· Enquire about and record any adverse events since the last visit (see Section 6.8.9) to include an 
examination for any signs of splenomegaly 
· Enquire about and record any changes in concomitant medication since the last visit 
· Make an appointment for a clinic visit on the following day and instruct the subject to bring a 
stool sample to the visit 
 
6.8.7 Visit 15: Day 14 
The subject will return to the clinic 14 days after dosing, when the following assessments will be 
completed: 
· Collect the stool sample that the subject has brought to clinic for culture of vaccine strain S. 
typhi (Ty2 aroC– ssaV–) ZH9 
· Determine and record vital signs (blood pressure, temperature and pulse) 
· Review Diary Cards and summarise data in CRF 
· Enquire about and record any adverse events since the last visit (see Section 6.8.9) to include an 
examination for any signs of splenomegaly 
· Enquire about and record any changes in concomitant medication since the last visit 
· Draw blood for:  
o Serum biochemistry and haematology 
o Serum IgG (ELISA assay) 
o Serum IgA (ELISA assay) 
· Obtain urine sample for: 
o Dipstick test, and if the dipstick is positive for leucocyte esterase and nitrites, a 
separate sample will be sent for microscopy, culture and sensitivity, and also to 
determine if vaccine strain S. typhi (Ty2 aroC– ssaV–) ZH9 is present 
· Make an appointment for Study Day 28. 
 
6.8.8 Visit 16: Day 28 
The subject will return to the clinic 28 days after dosing, where the following assessments will be 
completed: 
· Physical examination including vital signs (blood pressure, temperature and pulse) 
· Enquire about and record any adverse events since the last visit (see Section 6.8.9) to include an 
examination for any signs of splenomegaly 
· Enquire about and record any changes in concomitant medication since the last visit 
· Draw blood for: 
o Serum biochemistry and haematology 
o Serum IgG (ELISA assay) 
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· Obtain urine sample for: 
o Pregnancy test (females of 11 years and older only) 
o Dipstick test, and if the dipstick is positive for leucocyte esterase and nitrites, a 
separate sample will be sent for microscopy, culture and sensitivity, and also to 
determine if vaccine strain S. typhi (Ty2 aroC– ssaV–) ZH9 is present 
 
6.8.9 Specific Safety Reviews at Each Visit 
Visits to the clinic are scheduled daily, for the first 14 days post-dosing.  At these visits, the study 
staff will obtain and record the subject’s blood pressure, oral body temperature, pulse and assess for 
signs of splenomegaly.  The Investigator will enquire of the subject, and the parents or guardians, as 
to whether the subject has had any signs or symptoms of typhoid fever.  Specifically, enquiries will 
relate to whether the subject has had any of the following; 
· Temperature of 38.5°C or above. 
· Flushed face 
· Hot, dry skin 
· Low output of urine and/or dark urine 
· Loss of interest in eating 
· Constipation or diarrhoea 
· Vomiting 
· Headache 
· Aching all over 
· Nausea 
· Chills 
· Abdominal pains, cramps or discomfort 
 
6.8.10 Unscheduled Visits 
In addition to the scheduled visits described above, the subjects’ oral body temperature will be 
taken at home, twice daily.  If a subject shows sustained signs and symptoms of a clinical infection 
defined as a confirmed fever of = 38.5°C, or other signs and symptoms as outlined above, they will 
be instructed to make additional unscheduled visits to the clinic.  At such visits the subject will be 
assessed and biological samples taken for culture if clinically indicated.  If a clear diagnosis can be 
made, as in the case of Dengue fever, the subject will be managed accordingly.  Should a confirmed 
fever of = 39.0°C be recorded twice over a 48-hour period, or a severe fever of = 39.5°C ever be 
recorded, blood sample for cultures will be taken to investigate if S. typhi (Ty2 aroC– ssaV–) ZH9 is 
present in the blood. 
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7 IMMUNOGENICITY, SAFETY AND LABORATORY 
ASSESSMENTS 
7.1 Assessments of Immunogenicity 
Full details of the immunogenicity assays including sample collection, processing, storage and 
analysis are provided in the Laboratory Manual.  ELISPOT assays will be conducted at the study 
centre, ELISA samples for assay will be shipped to Emergent Product Development UK Ltd after 
preparation and freezing, under the supervision of Dr Jeremy Farrar the Principal Investigator for 
this study and in accordance with the instructions provided by Emergent Product Development UK 
Ltd. 
 
7.1.1 Measure of Antibody Secreting Cells by ELISPOT 
ELISPOT assay of the number of ASCs secreting IgA to LPS will be conducted on blood samples 
taken on Days 0 and 7 for subjects aged at least 11 years and weighing at least 27kg. The assay will 
be undertaken within 24 hours of the sample being taken. 
Human PBMCs will be separated from whole blood by density gradient centrifugation. After 
centrifugation the lymphocytes will be collected and washed.  The cells will then be suspended in 
culture medium and different dilutions added to microtitre wells coated with S. typhi LPS.  
Following overnight incubation, the cells will be removed.  Zones of antigen-specific secreted IgA 
antibody bound to the plate will be visualised by the addition of alkaline phosphatase- labelled anti-
human IgA antibodies followed by the addition of 5-bromo-4-chloro-3-indolyl-phosphate 
(BCIP)/Nitro Blue Tetrazolium (NBT) substrate.  Regions of specific antibody appear as blue 
ELISPOTS, and these will be observed and counted using an inverted microscope and then 
photographed. The number of ASC/106 cells can then be calculated from the results obtained with 
different dilutions of PBMCs. 
 
7.1.2 Analysis of LPS Specific Immunoglobulin G by the ELISA Assay 
Serum for ELISA assays for IgG will be frozen immediately after collection on Days 0, 14 and 28,  
and shipped to Emergent Product Development UK Ltd for analysis  after all subjects have 
completed 28 days for LPS-specific IgG serum antibody. 
Microtitre plates are coated with S. typhi LPS and blocked with a non-specific protein to mask 
unbound binding sites.  Human serum samples are added to the wells and any antibodies present 
that are specific for the S. typhi LPS will bind to the coated plate. These bound antibodies are then 
detected using a double antibody system. First, an unlabelled anti-human IgG antibody is added 
which, in turn, is detected by a horseradish peroxidase (HRP)- labelled conjugate which causes a 
detectable colour change when 3,3,5,5, Tetramethylbenzidine (TMB) substrate is added. The 
products are quantified with an automated ELISA reader at 450 nm and the concentration of anti-
LPS human IgG is determined by extrapolation of the dilution that is within the range of the 
standard curve. 
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7.1.3 Analysis of LPS Specific Immunoglobulin A by the ELISA Assay 
Serum for ELISA assays for IgA will be frozen immediately after collection on Days 0, 7 and 14 
and shipped to Emergent Product Development UK Ltd for analysis after all subjects have 
completed 14 days for LPS-specific IgA serum antibody. 
Microtitre plates are coated with S. typhi LPS and blocked with a non-specific protein to mask 
unbound binding sites.  Human serum samples are added to the wells and any antibodies present 
that are specific for the S. typhi LPS will bind to the coated plate. These bound antibodies are then 
detected using a double antibody system. First, an unlabelled anti-human IgA antibody is added 
which, in turn, is detected by a horseradish peroxidase (HRP)- labelled conjugate which causes a 
detectable colour change when 3,3,5,5, Tetramethylbenzidine (TMB) substrate is added. The 
products are quantified with an automated ELISA reader at 450 nm and the concentration of anti-
LPS human IgA is determined by extrapolation of the dilution that is within the range of the 
standard curve. 
 
7.2 Assessment for Safety 
7.2.1 Laboratory Tests 
Subjects will be asked to attend the clinic every day for the first 14 days of the study.  At these 
visits the Investigator (a paediatrician) will obtain and record the subject’s blood pressure, oral body 
temperature, pulse and assess for signs of splenomegaly.  The Investigator will enquire of the 
subject, and the parents or guardians, as to whether the subject has had any signs or symptoms of 
typhoid fever.  Specifically, enquiries will relate to whether the subject has had any of the 
following; 
· Temperature of 38.5°C or above 
· Flushed face 
· Hot, dry skin 
· Low output of urine and/or dark urine 
· Loss of interest in eating 
· Constipation or diarrhoea 
· Vomiting 
· Headache 
· Aching all over 
· Nausea 
· Chills 
· Abdominal pains, cramps or discomfort 
Based on the examination and the responses to the questioning, the Investigator will initiate 
appropriate investigations, including biological samples for culture, to determine if the child has an 
infection and the cause of the infection. 
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The faecal shedding pattern of the bacterial strain has been determined in adults with no subject, to 
date, shedding the vaccine strain for more than 7 days after dosing.  The faecal shedding pattern in 
children is expected to be the same but this study will investigate whether paediatric subjects shed 
for a shorter or longer period than adults. 
The following tests will be performed on blood samples collected at screening and Days 0, 7, 14 
and 28: 
Biochemistry: 
Sodium, potassium, chloride, creatinine, blood urea, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase, total bilirubin, gamma-glutamyl transferase (gGT), 
serum amylase, total protein and albumin. 
Haematology: 
Haemoglobin, haematocrit, red blood cell count, white blood cell count (total and differential), 
platelet count. 
In total, approximately 27.5 mL of blood will be taken from each subject, aged 5 to 10 years and 
weighing more than 17 kg, for the immunogenicity and safety tests during the 28-day phase of the 
study.  The maximum amount taken will be no more than 5.5mL at any one visit. 
In total, approximately 43.5 mL of blood will be taken from each subject, aged 11-14 years  and 
weighing more than 27 kg, for the immunogenicity and safety tests during the 28-day phase of the 
study. .  The maximum amount of blood taken will be no more than 13.5 mL at any one visit. 
If a subject shows sustained signs and symptoms of a clinical infection, defined as a confirmed 
fever of = 38.5°C, they will be instructed to make additional unscheduled visits to the clinic.  At 
such visits the subject will be assessed and biological samples taken for culture if clinically 
indicated.  Should a confirmed fever of = 39.0°C be recorded twice over a 48-hour period, or a 
severe fever of = 39.5°C ever be recorded, blood cultures will be taken to investigate if S. typhi 
(Ty2 aroC– ssaV–) ZH9 is present in the blood.  Each blood culture would require a blood draw of 
1-3 mL. 
Urine samples will be tested, by dipstick, at screening and Days 0, 7, 14 and 28 for the presence of 
nitrites and leucocyte esterase.  If the dipstick is positive for nitrites and leucocyte esterase a sample 
will be sent for culture and sensitivity.   
Stool samples will be collected for culture at all visits except Day 28.  Details of the assay method 
will be documented in the Laboratory Manual.  
Any post vaccination unformed/loose stool experienced by the subject will be recorded as an 
adverse event. 
 
7.2.2 Physical Examination 
A standard physical examination will be performed at the Screening visit and at Day 28.  Any 
abnormalities will be described in the CRF.  This will include assessments of the following: 
· Cardiovascular system 
· Respiratory system 
· Nervous system 
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· Skin and appendages 
· Abdominal/gastrointestinal system 
· Musculoskeletal system 
· Ear, nose and throat 
 
7.2.3 Vital Signs 
Vital signs will be determined and recorded at each study visit and recorded on the CRF.  Vital 
signs include: 
· Sitting (5 minute) systolic and diastolic blood pressure 
· Oral temperature (see also section 7.2.4) 
· Pulse rate 
 
7.2.4 Diary Card 
Each subject will complete a Diary Card daily for the 14 days following administration of study 
medication.  The subject will record his/her temperature or have their temperature recorded, twice 
in the morning (15 minutes apart) soon after getting up and twice at bedtime (15 minutes apart), as 
well as recording all adverse events.  Subjects will be instructed that: 
· Should their temperature be confirmed as = 38.5°C on both readings, measured 15 minutes 
apart, or reach 39.0°C or above on any reading, to contact and visit the investigative site as soon 
as is practical, to have a clinical assessment and initiation of appropriate investigations and 
therapy. 
· Should they feel feverish they should make additional recordings of their temperature and 
contact the investigative site 
· Should they experience any of the following events with moderate or severe intensity they 
should contact the investigative site and be prepared to make an additional visit: 
o Flushed face 
o Hot, dry skin 
o Low output of urine and/or dark urine 
o Loss of interest in eating 
o Constipation or diarrhoea 
o Vomiting 
o Headache 
o Aching all over 
o Nausea 
o Chills 
o Abdominal pain, cramps or discomfort 
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· Subjects will also conduct a stool assessment after each bowel movement. The time of passing 
the stool will be recorded and the stool assessed as ‘Normal’, ‘Soft but in one piece’, ‘thick 
liquid’, or ‘with rice and water’. The observer will also be asked to record if any blood was 
visible.  
8 ADVERSE EVENTS 
8.1 Definitions  
8.1.1 Adverse Event  
An adverse event (AE) is any untoward medical occurrence in a subject administered a 
pharmaceutical product and which does not necessarily have to have a causal relationship with this 
treatment. 
An AE can therefore be any unfavourable and unintended sign (including a clinically significant 
abnormal laboratory finding*, for example), symptom, or disease temporally associated with the use 
of a medicinal product, whether or not considered related to the medicinal product.  This includes 
events from the first study related activity after the subject and his/her guardian has signed the 
informed permission and assent forms.  The following should not be recorded as AEs, if recorded at 
screening: 
· Pre-planned procedure, unless the condition for which the procedure was planned has worsened 
from the first study related activity after the subject and his/her guardian has signed the 
informed permission and assent forms. 
· Pre-existing conditions found as a result of screening procedures (unless they get worse) 
 
*  A ‘clinically significant abnormal laboratory’ finding is defined as any clinical laboratory 
abnormality that suggests a disease and/or organ toxicity and is of a severity which requires active 
management (i.e. more frequent follow-up or diagnostic investigation) or is clinically significantly 
outside of the normal range.   
 
8.1.2 Serious Adverse Event 
A serious adverse event (SAE) is an experience that, at any dose, results in any of the following 
outcomes: 
· Death 
· A life-threatening* experience 
· In-patient hospitalisation or prolongation of existing hospitalisation 
· A persistent or significant disability/ incapacity 
· A congenital anomaly/ birth defect 
· Important medical events that may not result in death, be life-threatening* or require 
hospitalisation may be considered a SAE when, based upon appropriate medical judgement, 
they jeopardise the subject and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. 
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* The term life-threatening in the definition of SAE refers to an event in which the subject was at 
risk of death at the time of the event.  It does not refer to an event that hypothetically might have 
cause death if it was more severe.  
Bacteraemia should also be reported to Akos Ltd following the SAE reporting procedure.   If the 
blood culture grows the M01ZH09 vaccine strain or if the cause of the bacteraemia is undetermined 
Akos Ltd will report the event as a serious, unexpected, related, adverse event. 
 
8.1.3 Severity Assessment Definitions  
The Investigator will be asked to evaluate the severity of the AE according to the following scale: 
· Mild: Transient or mild discomfort (<48 hours); no medical intervention/therapy required. 
· Moderate: Mild to moderate limitation in activity - some assistance may be needed; none or 
minimal medical intervention/therapy required. 
· Severe: Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalisation possible. 
 
8.1.4 Relationship to Study Product Assessment Definitions  
The Investigator will be requested to evaluate the relationship between the AE and the study 
medication according to the following scale: 
· Probably: Good reason and sufficient documentation to assume a causal relationship 
· Possibly: A causal relationship is conceivable and cannot be dismissed 
· Unlikely: The event is most likely related to an aetiology other than the investigational product 
 
8.1.5 Outcome Categories and Definitions  
The outcome will be evaluated according to the following scale: 
· Recovered: Fully recovered or by medical or surgical treatment the condition has returned to the 
level observed from the first study related activity after the subject signed the informed 
permission and assent. 
· Stabilised: This outcome should only be used for cancer events and chronic conditions that 
cannot be normalised by medical or surgical treatment.  This term should only be used when the 
subject has completed the protocol 
· Recovered with sequelae 
· Not yet recovered 
· Fatal 
· Unknown 
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8.1.6 Fever Definition 
Fever is defined as an oral temperature of = 38.5ºC.  Severe fever is defined as an oral temperature 
of = 39.5ºC.  All subjects will be asked to take their temperatures twice a day in the morning when 
they get up and in the evening when they go to bed for the first 14 days post-dosing. 
 
8.2 Collection, Recording and Reporting of Adverse Events 
All AEs must be recorded in the subject’s CRF and must be monitored until there is either a return 
to normal or until the condition becomes stable or is resolved. 
All SAEs, whether or not they are judged to be related to the study drug, should be reported, by the 
Investigator, to Akos Ltd, upon learning of the SAE.  SAEs must be reported within 24 hours of 
knowing about the event or, ideally, within 24 hours of the occurrence of the event.  The 
Investigator must complete the Akos Ltd SAE form with as much information as is available at the 
time of completion and fax the form immediately to the number provided. 
Akos Ltd, the Study Monitor, the Medical Monitor, or a representative of Emergent Product 
Development UK Ltd, may follow up by requesting clarification or additional information on the 
SAE, from the Investigator. 
It is the responsibility of the Sponsor to report serious, unexpected adverse drug reactions (ADR)s 
to the relevant regulatory authorities and other Investigators as required under ICH, GCP and 
relevant regulatory reporting requirements. 
It is the responsibility of the Investigator (with the assistance of Emergent Product Development 
UK Ltd) to report any serious, unexpected ADRs to the Ethics Committee in accordance with ICH 
guidelines and local requirements. 
 
8.3 Follow-up of Adverse Events 
Events discovered or spontaneously reported to the Investigator within 28 days of taking the 
medication will be documented in the CRF.  All SAEs must be followed until all queries related to 
these AEs have been resolved. 
All other AEs must be followed until the Day 28 visit. 
The Investigator must forward follow-up information on SAEs to Akos Ltd within 5 days of 
obtaining the fo llow-up information.  Only changed or new information should be supplied. 
 
8.4 Safety Committee 
A safety committee will not be required for this study. 
 
8.5 Pregnancy 
Pregnancy is not an AE but the outcome may be.  Study subjects must notify the Investigator 
immediately if they become pregnant.  Subjects who become pregnant will be followed up to 
determine the outcome of the pregnancy.  The Investigator will be required to inform Emergent 
Product Development UK Ltd of a subject's pregnancy and the estimated date of delivery.  
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Emergent Product Development UK Ltd will follow up with the Investigator around the estimated 
time of delivery to determine the outcome of the pregnancy. 
 
8.6 Overdose 
Overdose is unlikely, as subjects will receive only one dose of study medication and under the 
supervision of research staff.  If a subject accidentally receives more than one dose of study 
medication, the subject will be observed and treated with antibiotics only if they shed beyond 7 
days, develop clinical signs and symptoms of a bacteraemia, develop a persistent silent bacteraemia 
or become a chronic carrier. 
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9 STATISTICS  
9.1 Sample Size Calculation 
The planned number of subjects is 150 in total, 100 should receive M01ZH09 oral typhoid vaccine 
and 50 placebo. No formal statistical calculations of sample size were appropriate. The number to 
include was based upon clinical judgement for both the assessment of safety and determination of 
immunogenicity. The latter from a consideration of the immunogenicity rates observed in 
M01ZH09 adult studies completed thus far and the immunogenicity rates observed in children, for 
typhoid vaccines currently on the market. 
 
9.2 Statistical Methods  
9.2.1 General Points 
Analyses will be primarily conducted to estimate parameters of interest such as the proportion of 
subjects that develop an immune response.  Due to the exploratory nature of the study, no 
adjustment will be made for multiplicity.  All available data from withdrawn subjects will be 
included in the analysis up to the time of withdrawal where possible. 
Any deviation(s) from the original statistical analysis plan (SAP) (which will be finalised prior to 
database lock) will be described and justified in the final report. 
 
9.2.2 Admission Profile 
Demographics and other baseline data will be listed and summarised.  Continuous variables (such 
as age, weight) will be summarised by numbers of subjects, means, medians, standard deviations, 
minima and maxima.  Categorical variables (such as race, sex) will be summarised by counts and 
percentages in each category. 
 
9.2.3 Study Populations  
The safety population will include all subjects who received a dose of study medication. 
The intention-to-treat (ITT) population will include all subjects who received a dose of study 
medication who have post-baseline immunogenicity data available.  The ITT population will be 
considered the primary population of interest for the immunogenicity endpoints.   
The per-protocol (PP) population analysis will be a subset of the ITT population and will be 
subjects who are not major protocol violators with regards to the inclusion/exclusion criteria, are 
compliant with study medication and concomitant medications.  The SAP will define the exact 
criteria for exclusion from the PP population.   
 
9.2.4 Safety Endpoints 
9.2.4.1 Primary 
The proportion of subjects reporting SAEs attributed to the study medication 
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9.2.4.2 Secondary 
The proportion of subjects; 
· Experiencing symptomatic elevated body temperature, of 38.5 C or greater, in the 14 days 
following dosing, attributed to study medication. 
· Demonstrating persistent (after Day 7) faecal shedding of S. typhi (Ty2 aroC– ssaV–) ZH9. 
· Withdrawn from the study due to adverse events, including bacteraemia attributed to study 
medication 
· With clinically significant changes in laboratory parameters, from Day 0 to any time post 
dosing, which are attributed to study medication. 
9.2.5 Immunogenicity Endpoints 
Assessment of the immune response will be made by determining the proportion of subjects who; 
· Develop a positive immune response* to S. typhi LPS as assessed by an increase in S. typhi LPS 
specific IgG at either Day 14 or Day 28. 
· Develop a positive immune response* to S. typhi LPS as assessed by an increase in S. typhi LPS 
specific IgA at either Day 7 or Day 14. 
· At Day 7, have = 4 ASCs per 106 PBMC, secreting IgA specific for S. typhi LPS detected by 
ELISPOT assay**. 
*The definition of a ‘positive immune response’ will be determined following the completion of 
assay development. 
**An ELISPOT Day 0 result of = 4 ASCs per 106 PBMC constitutes a pre-vaccination positive and 
the subject will be excluded from the analysis of the ELISPOT results. 
 
9.3 Methods of Analysis for Safety Variables 
All safety summaries will be carried out on the safety population defined in Section 9.2.3. 
Summary statistics will be used to present the number of subjects receiving M01ZHZ09 oral 
typhoid vaccine and placebo. 
The numbers of subjects reporting adverse events will be summarised by body system and by 
MedDRA (version 8.1 or later) preferred term.  All adverse experiences recorded after vaccination 
will be summarised and listed.  Adverse events with missing or incomplete onset dates will be 
assumed to be post-dosing adverse events.  Summaries will also be produced showing adverse 
events by severity, seriousness and relationship to treatment. 
The numbers of subjects withdrawn from the study due to adverse events, including bacteraemia 
attributed to S. typhi (Ty2 aroC– ssaV–) ZH9, will be presented separately. 
Counts will be based on the number of subjects experiencing an event and not the number of events 
experienced e.g. if a subject reports the same adverse event on three occasions that adverse event 
will be counted once.  Subjects reporting more than one adverse event in a body system will be 
counted only once in the body system total. 
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The number and percentage of subjects will be presented, by Visit and overall, that: 
· Experience symptomatic elevated body temperature in the 14 days following dosing, 
attributed to study medication 
· Demonstrate persistent (after Day 7) faecal shedding of   S. typhi (Ty2 aroC– ssaV–) ZH9 
· Have clinically significant changes in laboratory parameters from Day 0 to any time post 
dosing which are attributed to study medication. 
 
Laboratory results will be listed with values that are outside the laboratory normal range flagged.  
For each parameter the overall numbers of values that are within the pre-determined clinically 
important range at Day 0 but outside the range post-treatment will be summarised. 
Vital signs and physical examination results will be summarised by visit. 
 
9.4 Methods of Analysis for Immunogenicity Endpoint 
The primary outcome measure in this study will be the proportion of subjects with a positive 
immune response (a positive serum IgG and/or a positive serum IgA response and/or an increase in 
the number of ELISPOTS). The proportion of subjects who satisfy the immunogenicity endpoint 
will be compared between the vaccine and placebo groups.  The treatment difference and associated 
95% confidence interval will be presented. 
The number and percentage of subjects with an immune response will be presented along with the 
two-sided 95% confidence interval for each treatment group. 
In addition, the number and percentage of subjects with defined immune response will be presented 
by type of assay. 
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10 DIRECT ACCESS TO SOURCE DATA/ DOCUMENTS 
This study is undertaken on the express understanding that the Investigator/Institution will permit 
study-related monitoring, audits, Ethics Committee review and regulatory inspection(s), providing 
direct access to source data/documents. 
Direct access includes permission to examine, analyse, verify and copy any records and reports that 
are important to evaluation of the clinical study. 
Prior to study start, a source data verification (SDV) document will be created and agreed with the 
Investigator.  This document will specify the source documents for the key items of data collected 
during the study.  SDV by the Study Monitor will be conducted in accordance with this SDV 
document.  Source data such as laboratory results will be signed and dated by the Investigator to 
confirm that these have been medically reviewed. 
 
11 QUALITY CONTROL AND QUALITY ASSURANCE 
Data will be recorded on CRFs provided by Emergent Product Development UK Ltd.  Study 
specific instructions on the completion of CRFs will be given to the Investigator and appointed 
staff. 
By signing the Investigator Statement at the end of the CRF, the Investigator confirms that the 
information provided by the Investigator and his appointed staff is complete and correct. 
Correction to CRFs prior to collection will be made by drawing a straight line through the incorrect 
data and by writing the correct value next to data that has been crossed out.  Each correction must 
be initialled, dated and explained (if necessary) by the Investigator or the Investigator's authorised 
staff. 
Correction to CRFs after collection from the Investigator's site must be documented on a Query 
Resolution Form. 
Source data such as laboratory results will be signed and dated by the assessor. 
During the course of the study, the Study Monitor will visit the investigational site at intervals 
appropriate to recruitment and volume and quantity of data.  The purpose of these visits is to ensure 
that the CRFs are completed correctly, the protocol is adhered to, IMP is properly accounted for and 
to collect completed pages of the CRFs. 
The Monitor will review source documents directly, e.g. subjects' notes, to ensure correct 
transcription and quality of data. 
Study files and data may be audited by an independent auditor. 
Deviations from the protocol should not occur.  If deviations occur, the Investigator must inform the 
Study Monitor, and the implications of the deviations must be reviewed and discussed.  Any 
deviation must be documented, stating the reason and date, the action taken, and the impact for the 
subject and/ or the study.  The documentation must be kept in Investigator's Trial Master File and 
the Sponsor's Trial Master File. 
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12 ETHICS 
The study will be conducted in accordance with the Declaration of Helsinki and the International 
Conference on Harmonisation GCP guidelines. 
 
12.1 Informed Consent Form for Study Subjects 
In obtaining and documenting informed consent, the Investigator must comply with the applicable 
regulatory requirements and adhere to the ICH GCP guideline and the requirements in the 
Declaration of Helsinki.  
Prior to any study related activity, the Investigator must give the subject and the subject’s parents or 
guardians oral and written information about the study in a form that they can read and understand.  
Sufficient time must be given to the subject and their family to discuss the study, away from the 
investigative site, and to decide whether participation is appropriate. 
A voluntarily signed and dated Permission Form will be obtained from the subject’s parents or 
guardians prior to any study related activity.  The Permission Form must be signed by both of the 
subject’s parents unless one parent is deceased, unknown, incompetent, not reasonably available or 
where only one parent has legal responsibility for care and custody of the child.  The written 
Permission Form must also be signed and dated by the person who conducted the informed consent 
procedure. 
In addition to the Permission Form, an Assent Form should be signed by the subject, where 
appropriate.  In general, subjects aged 11 to 14 years should read and sign the Assent Form.  This 
form will contain all pertinent information about the trial in age appropriate language.  Subjects 
aged 5 to 10 years should read and sign the Assent Form if they are able and where it is deemed, by 
the site staff, to be appropriate. 
Regardless of the subject’s ability to read or sign Assent Forms, their wishes should be fully 
considered and if it is at all possible that they do not wish to take part, they should be given the 
opportunity to express that wish and be excluded from the study.  Consideration should be given to 
the possibility that a child who declines to take part on one occasion, may change his/her mind at a 
later date and subsequently be a willing participant. 
If information becomes available that may be relevant to the subject's willingness to continue 
participating in the study, the Investigator must inform the subject and their parents in a timely 
manner, and revised written Permission and Assent forms must be obtained. 
 
12.2 Independent Ethics Committee 
Before commencement of the study the following will be submitted to the IEC; the protocol and any 
amendments, Subject/Parent Information and Permission/Assent Forms, any other written 
information to be provided to the subject, subject recruitment procedures, if any, Investigator's 
Brochure (IB), information about payments and compensation available to subjects, if not 
mentioned in the subject information, the Investigator's current CV and other documents as 
required.  The submission letter should clearly identify (by including version number and date of 
the document) which documents have been submitted to the IEC.  Written approval must be 
obtained for the IEC prior to commencement of the study. 
MS01.08 V2 FINAL 17 January 2007 
 
 
Page 68 of 72 
During the study, the Investigator must promptly report the following to the IEC; updates to IB, 
unexpected SAEs where a causal relationship cannot be ruled out, amendments to the protocol, 
notes of administrative changes, deviations to the protocol implemented to eliminate immediate 
hazards to the study subjects, new information that may affect adversely the safety of the subjects or 
the conduct of the study, annually written summaries of the study status, and other documents as 
required by the IEC.  
Amendments must not be implemented before approval, unless necessary to eliminate hazards to 
the subjects.   
The Investigator must maintain an accurate and complete record of all submissions made to the 
IEC.  The records should be filed in the Investigator's Trial Master File, and copies must be sent to 
Emergent Product Development UK Ltd. 
 
12.3 Regulatory Authorities 
Regulatory Authorities will receive the protocol, amendments, reports on SAEs, and the Integrated 
Clinical Trial Report according to national regulations.  
 
13 DATA HANDLING AND RECORD KEEPING 
All data entry will be computerised without using subject names. 
 
13.1 Data Entry 
Second entry verification will be performed with primary and secondary entry being carried out by 
separate operators.  The two entries will be compared and any discrepancies resolved by reference 
to the CRF. 
Data entry guidelines will be used to assist in the data entry process. 
 
13.2 Data Coding 
Adverse events will be coded using MedDRA (version 8.1 or later). 
 
13.3 Audit Trail 
SAS datasets will be created and a full audit trail kept to track creations, edits and deletions.  Any 
changes to the data will be tracked per subject. 
 
13.4 Data Validation and Checks 
Validation checks will be written in SAS to check the consistency and accuracy of the values.  
Consistency checks will also be performed as required. 
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14 FINANCE AND INSURANCE 
All financial agreements for the conduct of the study are detailed in contracts between Emergent 
Product Development UK Ltd (formerly Microscience Ltd) and the Investigator.  Details of 
financial compensation for services rendered will be recorded.  The Investigator may reimburse 
reasonable expenses, incurred by the subjects or their parents, when receipts or a mileage claim 
supports the expenses. 
The Investigator must provide Emergent Product Development UK Ltd with sufficient and accurate 
financial disclosure information for Emergent Product Development UK Ltd to meet their 
regulatory disclosure requirements (21CFR54).  The clinical Investigator will update this 
information if any relevant changes occur during the investigation and for one year following 
completion of the study. 
The study site will maintain adequate public liability insurance cover throughout the term of the 
study and, on request, will provide satisfactory evidence of its adequate insurance cover to 
Emergent Product Development UK Ltd. 
Emergent Product Development UK Ltd will maintain adequate clinical trials liability insurance 
coverage throughout the term of the study and, on request, will provide satisfactory documentary 
evidence of its adequate insurance cover to the study site. 
 
15 REPORTS AND PUBLICATIONS 
Emergent Product Development UK Ltd recognises that Oxford University and the site Principle 
Investigator have a responsibility under the Research Governance Framework for Health and Social 
Care to ensure that results of scientific interest arising from the clinical trial are appropriately 
published and disseminated.  Emergent Product Development UK Ltd agrees that employees of 
Oxford University will be permitted to present at symposia, national or regional professional 
meetings and to publish in journals, theses or dissertation or otherwise, of their own choosing, 
methods and results of the clinical trial, subject to the publication policy described in this protocol. 
Upon completion of the clinical trial and prior to publication of multi-centre data, or when the 
clinical trial data are adequate (in Emergent Product Development UK Ltd’s reasonable judgement), 
Oxford University may prepare the data deriving from the clinical trial for publication.  Such data 
will be submitted to Emergent Product Development UK Ltd for review and comment prior to 
publication.  In order to ensure that Emergent Product Development UK Ltd will be able to make 
comments and suggestions where pertinent, material for public dissemination will be submitted to 
Emergent Product Development UK Ltd for review at least sixty (60) days prior to submission for 
publication, public dissemination or review by publication committee. 
Oxford University agrees that it will give fair consideration to all reasonable comments made by 
Emergent Product Development UK Ltd in relation to a proposed publication by Oxford University 
but Emergent Product Development UK Ltd recognises that there will be no obligation upon Oxford 
University to modify the publication. 
During the period for review of a proposed publication, referred to above, Emergent Product 
Development UK Ltd will be entitled to make a reasoned request to Oxford University that 
publication be delayed for a period of up to six (6) months from the date of its first submission to 
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Emergent Product Development UK Ltd in order to enable Emergent Product Development UK Ltd 
to take steps to protect its proprietary information and Oxford University will not unreasonably 
withhold its consent to such a request. 
 
16 ARCHIVING 
The investigator will retain all documents associated with the study for at least 5 years.  Medical 
files of trial subjects shall be retained in accordance with national legislation and in accordance with 
the maximum period of time permitted by the hospital or institution.  Study documents shall be 
retained for a longer period if required by the applicable regulatory authority or by agreement with 
the sponsor.  If the investiga tor responsible for the study should move or retire during this period he 
will nominate someone in writing to be responsible for record keeping 
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